bibliography
TRANSCRIPT
Richard S. Blumberg, M.D.
CURRICULUM VITAE
PART I: General Information
DATE PREPARED: December 9, 2007
Name: Richard Steven Blumberg
Office Address: Brigham and Women’s Hospital75 Francis StreetBoston, MA 02115
Home Address: 34 LaGrange StreetChestnut Hill, MA 02467
E-Mail: [email protected] Fax: (617) 264-5185
Place of Birth: Philadelphia, PA
Education:
1974 B.S. Carnegie-Mellon University, Pittsburgh, PA1979 M.D. Jefferson Medical College of the Thomas Jefferson University,
Philadelphia, PA1993 M.B.A. Graduate School of Business Administration, Northeastern University, Boston, MA2005 M.S. Harvard University, Boston, MA (Honorary)
Postdoctoral Training:
Internships and Residencies:
7/1979-6/1981 Internship and Residency in Internal Medicine, The New York Hospital, Cornell Medical Center, New York, NY
7/1981-6/1982 Assistant Chief Medical Resident in Internal Medicine, The New York Hospital, Cornell Medical Center, New York, NY
Clinical and Research Fellowships:
7/1982-6/1983 Clinical Fellow in Medicine, Infectious Diseases, Massachusetts General Hospital, Boston, MA
7/1982-6/1986 Research Fellow in Medicine, Harvard Medical School, Boston, MA
7/1983-6/1986 Research Fellow in Medicine (Mentor: Robert T. Schooley, M.D.), Infectious Diseases, Massachusetts General Hospital, Boston, MA
1
Richard S. Blumberg, M.D.
7/1986-6/1987 Clinical Fellow in Medicine, Gastroenterology, Brigham and Women’s Hospital, Boston, MA
7/1986-6/1987 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA7/1987-6/1989 Research Fellow in Medicine, Harvard Medical School,
Boston, MA7/1987-6/1989 Research/Clinical Fellow in Medicine, Gastroenterology, Brigham
and Women’s Hospital, Boston, MA7/1987-6/1990 Research Fellow in Medicine, Laboratory of Molecular
Immunology (Mentor: Cox P. Terhorst, Ph.D.), Dana-Farber Cancer Institute, Boston, MA
Licensure and Certification:
1979-1982 New York Medical License1980 Diplomate, National Board of Medical Examiners1982 Diplomate, American Board of Internal Medicine1983- Massachusetts Medical License1986 Diplomate, American Board of Internal Medicine, Infectious
Diseases1989 Diplomate, American Board of Internal Medicine,
Gastroenterology
Academic Appointments:
1990-1991 Instructor in Medicine, Harvard Medical School, Boston, MA1991-1996 Assistant Professor of Medicine, Harvard Medical School, Boston,
MA1996-2005 Associate Professor of Medicine, Harvard Medical School, Boston,
MA2005- Professor of Medicine, Investigator Track, Harvard
Medical School, Boston, MA
Hospital or Affiliated Institution Appointments:
7/1989-6/1996 Associate Physician, Brigham and Women’s Hospital, Gastroenterology Division, Boston, MA
10/1990-10/2001 Consultant Staff, VA Boston HealthCare System, Boston, MA7/1996-3/2005 Physician, Brigham and Women's Hospital, Gastroenterology
Division, Boston, MA2/1996- Consultant Staff, Dana-Farber Cancer Institute, Boston, MA4/2005- Senior Physician, Brigham and Women’s Hospital,
Gastroenterology Division, Boston, MA6/2005-8/2006 Provisional Medical Staff, Faulkner Hospital, Boston, MA8/2006- Courtesy Staff, Faulkner Hospital, Boston, MA
2
Richard S. Blumberg, M.D.
Other Professional Positions and Major Visiting Appointments:
1983 – 1986 Consultant in Medicine, Massachusetts Eye & Ear Infirmary,Boston, MA
1999 – 2007 Scientific Founder, Syntonix Pharmaceuticals, Waltham, MA(acquired by Biogen-Idec, Cambridge, MA 2007)
2000 - Scientific Advisory Board, Cellact, Dortmund, Germany
Hospital and Health Care Organization Service Responsibilities:
1989- Gastroenterology Consult Service Attending, Brigham andWomen's Hospital, Boston, MA
1989- Gastroenterology Endoscopy Service Attending, Brigham and Women's Hospital, Boston, MA
1990- Medicine Consult Service Attending, Brigham and Women's Hospital, Boston, MA
Major Administrative Responsibilities:
1990- Director, Laboratory of Mucosal Immunology, Brigham and Women's Hospital, Boston, MA
1996-1998 Director of Gastroenterology Research, Brigham and Women's Hospital, Boston, MA
1997-1998 Acting Chief, Gastroenterology Division, Brigham and Women’sHospital, Boston, MA
1998-2007 Program Director, Categorical Fellowship Program in Gastroenterology, Brigham and Women’s Hospital, Boston, MA1998- Chief, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA
1999-2000 Acting Chief, Gastroenterology Division, VA Boston HealthCareSystem, Boston, MA
1999- Training Grant Director (NIH T32), Gastroenterology Division, Brigham and Women’s Hospital, Boston, MA2002-2005 Chairperson, National Scientific Advisory Committee, Crohn’s & Colitis Foundation of America
Major Committee Assignments:
Medical School:
1993- Member, Committee on Immunology, Harvard Medical School,Boston, MA
1995-1997 Member, Committee for Qualifying Examinations in Immunology, Harvard Medical School, Boston, MA
3
Richard S. Blumberg, M.D.
1996- Member, Harvard Skin Disease Research Center, Harvard MedicalSchool, Boston, MA
1996-1997 Member, Executive Committee, Harvard Digestive Diseases Center, Harvard Medical School
1996- Co-Director, Harvard Digestive Diseases Center, Harvard Medical School
2001-2006 Xenotransplantation Advisory Committee, Harvard Medical School
Affiliated Institutions:
1993 Thorn Research Committee, Brigham and Women's Hospital, Boston, MA
1994-1998 Gastroenterology Training Program Advisory Committee,Brigham and Women's Hospital
1996-1998 Member, Research Council, Brigham and Women's Hospital1997-1998 Member, Practice Infrastructure Committee, Brigham and
Women's Hospital1997-1998 Member, Translational Research Committee, Brigham and
Women's Hospital1997- Advisory Board, Research Enhancement and Award Program,
Research and Training in Swallowing and Motility Disorders (REAP), West Roxbury Veterans Administration Medical Center
1998 Internal Residency Review Committee, Neuropathology Residency Training Program, Brigham and Women’s Hospital
1999- Affiliate Member, Membrane Biology Program, Brigham and Women’s Hospital
2000 Internal Residency Review Committee, Obstetrics and Gynecology Residency Training Program, Brigham and Women’s Hospital
2000-2002 Advisory Committee, DNA Microarray Biotechnology Center,Brigham and Women’s Hospital
2002-2003 Member, Search Committee for Chief of Gastroenterology, Children’s Hospital Medical Center, Boston, MA
2003-2004 Junior Staff Appointment and Promotion Committee, Brigham and Women’s Hospital
2004 Ad hoc member, Partners Internal Technical Assessment Committee (ITAC)
2006 Member, Search Committee for Chief of Gastroenterology, VA Boston Healthcare System, Boston, MA
2006 Department of Medicine Representative, Research Oversight Committee, Biomedical Research Institute, Brigham and Women’s Hospital2006- Brigham and Women’s Hospital IRB Panel B, Member
International, National and Regional:
4
Richard S. Blumberg, M.D.
National Institutes of Health
1993 Special Emphasis Panel, Pathogenesis of Inflammatory BowelDisease and Celiac Disease
1994 Special Emphasis Panel, Chronic Intestinal Inflammation-Mechanisms and Effects
1994 Special Emphasis Panel, The Pathogenesis of Wasting and AIDS1995 Special Emphasis Panel, IBD: Genetic and Immunopathologic
Mechanisms, National Institutes of Health1995 GMA-2 Study Section (ad hoc), NIIDDK 1996 Special Emphasis Panel, Mucosal and Synovial Gene Transfer1996 – 2000 Member, Immunological Sciences Study Section, NIAID1997 Special Emphasis Panel, Chronic Intestinal Inflammation -- Mechanisms and Effects1998 Special Emphasis Panel, AIDS Biliary Disease, Prevalence,
Etiology and Therapy1999 Special Emphasis Panel, Chronic Intestinal
Inflammation – Mechanism & Effects1999 Special Emphasis Panel, Mucosal Immunology1999 Special Emphasis Panel, Immunogenetic Mechanisms of
Experimental Colitis, Site Visit, Charlottesville, VA1999 Special Emphasis Panel, AIDS and Related
Research Review Group2000 Special Emphasis Panel, IBD: Genetics and Immunopathology2000 Special Emphasis Panel, GMA-2 Study Section2002 Special Emphasis Panel, “Growth Hormone and
Crohn’s Disease: Multicenter Study”2002 Special Emphasis Panel, GMA-2 Study Section2002 Ad Hoc Member, Scientific Review Committee,
Immune Tolerance Network2003 Special Emphasis Panel, GMA-2 Study Section2003 Ad Hoc Member, Allergy and Immunology Study
Section2004 Special Emphasis Panel, Innate and Adaptive Microbial Immunity
in IBD2006 Special Emphasis Panel, -Catenin and Intestinal
Inflammation2006 – 2008 National Commission on Digestive Diseases, Member2006 Board of Scientific Counsellors, NIAID (ad hoc)
Crohn’s & Colitis Foundation of America
1993-1996 Research Chairman, Boston Chapter, Crohn's & Colitis Foundation of America
1993-1996 Member, Grants Review Committee, Crohn's & Colitis Foundation of America
1996 Committee Chair, "Challenges in IBD Research-Immune
5
Richard S. Blumberg, M.D.
Regulation: Response to Pathogen", Crohn's & ColitisFoundation of America
1997-2000 Co-chairman, Grants Review Committee, Crohn's & Colitis Foundation of America
1999-2002 Chairman, Grants Council, National Scientific Advisory Committee, Crohn’s & Colitis Foundation of America
2000-2002 Research Initiatives Committee, Crohn’s & Colitis Foundationof America
2002 Committee Chair, Strategic Plan: Bacterial-Host Interactions,Crohn’s & Colitis Foundation of America
2005- Chairperson Emeritus, National Scientific Advisory Committee, Crohn’s & Colitis Foundation of America
Other
1999 Ad Hoc Reviewer, Wellcome Trust, United Kingdom1999 Ad Hoc Reviewer, The Israel Science Foundation, The Israel
Academy of Sciences and Humanities1999 Organizing Committee, New Frontiers in Oral Immunological
Diseases, Lillehammer, Norway.2001-2002 Main Scientific Organizing Committee, Falk Symposium,
Mechanisms of Intestinal Inflammation: Implications for Therapeutic Interventions in IBD, Berlin, Germany
2001 Ad Hoc Review Committee, Crohn’s in Childhood ResearchAssociation, Surrey, United Kingdom
2001- Clinical Immunology Society, Vice-Chair, Mucosal Immunology Interest Group
2002 Ad Hoc Review Committee, GRASP Digestive Diseases Research Center, Tufts/New England Medical Center
2002 Ad Hoc Reviewer, John Sealy Memorial Endowment Fund for Biomedical Research, University of Texas Medical Branch at Galveston, TX
2002 Main Organizer, Keystone Meeting, Microbial-Epithelial-Lymphocyte Interactions in Mucosal Immunology, Breckenridge, CO
2003- Ad Hoc Reviewer, Broad Medical Research Program
2003- Chair, Scientific Advisory Committee, Genetic and Immunopathologic Mechanisms Program Project Grant, University of California, Los Angeles
2003- Internal Advisory Board, Center for Experimental Therapeutics & Reperfusion Injury, Brigham and Women’s Hospital, Boston
2003- Member, Scientific Advisory Committee, Program Project Grant “Cellular and Molecular Mechanisms of Autoimmunity,” Mt. Sinai Hospital, New York
6
Richard S. Blumberg, M.D.
2003-2004 Organizing Scientific Committee, European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), “Gut inflammation: impact on GI and systemic diseases”, Capri, Italy
2003-2005 Organizing Scientific Committee, Falk Symposium, “Gut-Liver Interactions in Immunology,” Innsbruck, Austria
2004 Ad Hoc Reviewer, Science Foundation Ireland
Professional Societies:
American Gastroenterological Association (AGA)
1989- Member, AGA1992 Chair, Immunology/Microbiology/Inflammatory Disorders
Session, Annual Meeting of the AGA1992-1998 Member, Abstract Selection Committee, Annual Meeting
of the AGA1993 Chair, T cells -
Differentiation/Activation/Interactions Session, Annual Meeting of the AGA
1993- Chair, Gastrointestinal T cells Session, Annual Meeting,AGA
1993-1996 Member, Publications Committee, AGA1995 Chair, Epithelial Cell Function in Immunity and Inflammation Session, Annual Meeting of the AGA1995 Member, AGA Core Curriculum Task Force
1996 Chair, Abstract Selection Committee on Mucosal Immunity, AGA1996 Chair, Epithelial Cell Function in Immunity and Inflammation
Session, Annual Meeting of the AGA1997 Chair, T Cells: Immunology and Inflammatory Bowel Disease
Session, Annual Meeting of the AGA1998 Chair, Inflammatory Bowel Disease: Basic Mechanisms Session, Annual Meeting of the AGA
1998-2000 Vice-Chair Elect, Immunology, Microbiology and Inflammatory Bowel Disease Section, AGA
2000-2002 Vice-Chair, Immunology, Microbiology and Inflammatory BowelDisease Section, AGA
2000 Chair, Plenary Session; Immunology, Microbiology and Inflammatory Bowel Disease Section, Annual Meeting, AGA
2000 Co-Chair, Distinguished Abstract Plenary Session: Immunology, Microbiology and Inflammatory Bowel Disease Section, AGA
2001 Member, AGA Distinguished Achievement Award Selection Committee
2002-2003 Chair, Immunology, Microbiology and Inflammatory Bowel Diseases Section, AGA
7
Richard S. Blumberg, M.D.
2002 Co-Chair, Distinguished Abstract Plenary Session: Immunology, Microbiology and Inflammatory Bowel Disease Section, AGA2003-2004 Member, Nominating Committee, AGA2003 Co-Chair, Distinguished Abstract Plenary Session: Immunology, Microbiology and Inflammatory Bowel Disease Section, AGA
2004 Co-Chair, Distinguished Abstract Plenary Session: Immunology,Microbiology and Inflammatory Bowel Disease Section, AGA2004 Chair, Abstract Review Section on Epithelial-Immune Interactions, Immunology, Microbiology and Inflammatory Bowel Diseases Section, AGA2005-2006 Member, Future Trends Committee, AGA2007-2009 Chair, Education & Training Committee, AGA
2006-2009 Member, Leadership Cabinet, AGA
Society for Mucosal Immunology (SMI)
1991- Member, SMI1994 Member, Organizing Committee, 8th International Congress of
Mucosal Immunology, SMI1995-1998 Member, Nominations Committee, SMI1996 Member, Organizing Committee, 9th International Congress of Mucosal Immunology, SMI2002 Member, International Scientific Committee, 11th International Congress of Mucosal Immunology, SMI2002- Member, Governing Board, SMI
2002-2005 Main Organizer, 12th International Congress of Mucosal Immunology, SMI, Boston, MA2005-2007 President-Elect, SMI
2007-2009 President, SMI
Gastroenterology Research Group (GRG) of the American Gastroenterological Association
1993- Member, GRG1998 Organizer and Chair, GRG Annual Symposium: Immuno-
pathogenesis, Therapy and Prevention of Hepatitis C Virus Infection.
1998-2001 Member, GRG Steering Committee2000 Organizer and Chair, GRG Symposium, Animal Models of
Inflammatory Bowel Diseases
Federation of Clinical Immunology Societies (FOCIS)
8
Richard S. Blumberg, M.D.
1993- Member, Clinical Immunology Society2000 Member, Organizing Committee, FOCIS First
Annual Meeting, Boston2001 Chair, Mucosal Immunology, FOCIS Meeting2002 Member, Organizing Committee, FOCIS Second
Annual Meeting, San Francisco2002- Member, Steering Committee, FOCIS2002-2005 Councilor, Clinical Immunology Society
2003 Member, Program Committee, FOCIS Third Annual Meeting, Paris, France2004 Member, Program Committee, FOCIS Fourth Annual Meeting,
Montreal, Canada2004-2005 Program Co-Chair, FOCIS Fifth Annual Meeting, Boston
American Association of Immunologists (AAI)
1991- Member, AAI2003 Co-Organizer and Chair, Major Symposium on Mucosal
Immunity, Annual Meeting, AAI2004 Organizer and Chair, Guest Symposium on Mucosal Immunity,
Annual Meeting, AAI
Other
1982-1989 Member, American College of Physicians1989- Fellow, American College of Physicians2000-2003 Member, National Intercollaborative Research Effort (N.I.C.E.) Foundation2003 Symposium Chair, 36th Annual Meeting of the Society of Leukocyte Biology, “Cellular Mechanisms in Inflammation (Lymphocytes/NK Cells),” Philadelphia, PA
Community Service Related to Professional Work:
1994-1995 Organizer, New England Symposium on Inflammatory BowelDisease, Crohn’s & Colitis Foundation of America
1998- Board of Directors, New England Chapter, Crohn’s & ColitisFoundation of America
2002- Board of Trustees, Crohn’s & Colitis Foundation of America2003 Founding Board of Scientists, International
Autoimmune Disease Research Foundation (IADRF)
Editorial Boards:
9
Richard S. Blumberg, M.D.
1990- Ad hoc reviewer for:Gastroenterology Journal of ImmunologyJournal of Clinical InvestigationJournal of Experimental MedicineDigestive Diseases and SciencesNew England Journal of MedicineClinical and Experimental ImmunologyInfection and Immunity Journal of Biological ChemistryMolecular ImmunologyScienceAmerican Journal of PathologyJournal of Clinical MicrobiologyHepatologyDNANature MedicineNature Reviews ImmunologyBiochemica et Biophysica ActaTissue AntigensBiochemistryJournal of Allergy and Clinical ImmunologyInternational ImmunologyProceedings of the National Academy of Sciences, USANature
1994- Member, Editorial Board, Inflammatory Bowel Disease1995 Member, Editorial Board, Gastroenterology1995 Guest Associate Editor, Gastroenterology1996-2001 Associate Editor, Gastroenterology1997-2003 Member, Editorial Board, American Journal of Physiology:
Gastrointestinal and Liver Physiology1998-2003 Associate Editor, Journal of Immunology2002- Guest Associate Editor, Gastroenterology2002- Section Editor, Basic Sciences Section,
Inflammatory Bowel Disease2003- Editorial Board, Drug Discovery Today: Disease Models
2007- Section Editor, Mucosal Immunology
Awards and Honors:
1978 Selected Member, Alpha Omega Alpha Honor Medical Society1978 Selected Member, Hobart Amory Hare Honor Medical Society1979 Cum Laude, Jefferson Medical College of the Thomas Jefferson
University1979 Alexander and Lotte Katzman Award in Gastroenterology1979 Lange Medical Publications Award1985 Research Fellowship from Aid for Cancer Research
10
Richard S. Blumberg, M.D.
1988 American Gastroenterological Association Senior Research Fellow Award
1993 Selected Member, Beta Gamma Sigma Honor Society1995 Elected Member, American Society of Clinical Investigation1995 Nominee, Harvard Medical School Award for Excellence in
Mentoring1995 American Digestive Health Foundation/American
Gastroenterological Association Basic Research Award2001 Elected Member, Association of American Physicians2002 Humanitarian Man of the Year, Crohn’s & Colitis
Foundation of America2005 Method to Extend Research in Time (M.E.R.I.T.) status, National Institutes of Health
11
Richard S. Blumberg, M.D.
PART II: Research, Teaching, and Clinical Contributions
A. Narrative Report:
Research: I am the Co-Director of the Harvard Digestive Diseases Center and I direct an NIH-funded laboratory that focuses on a number of issues related to mucosal immunity. My laboratory has made major contributions in the following areas that are highly relevant to inflammatory bowel disease (IBD), mucosal infections and vaccinology and is the recipient of a MERIT Award from the NIH. Characterization of mucosal T cell receptor (TCR) repertoire. My laboratory has shown that human intestinal intraepithelial lymphocytes (IEL), as well as a subpopulation of lamina propria lymphocytes (LPL) and IEL associated with the human biliary epithelium, express a limited number of TCR- and chains. This indicates that IELs and LPLs are oligoclonally expanded despite their contiguity with the gut lumen and thus recognize an extremely limited number of antigens, which places significant constraints on their function. We extended these studies to human IBD through the use of TCR repertoire analysis to provide evidence for the existence of private and public TCR motifs in this disease. These latter studies support the existence of disease-related T-cell responses in human IBD. Delineation of Carcinoembyronic Antigen Cell Adhesion Molecule 1 (CEACAM1) as a T cell regulatory molecule. A major goal of my laboratory has been to characterize molecules involved in intestinal epithelial cell (IEC)-IEL interactions. We have shown that CEACAM1 is an activation antigen on T cells, which functions in the negative-regulation of mouse and human IELs and T cells, in general. This regulation by CEACAM1 occurs through homophilic interactions with CEACAM1 on target cells such as IECs leading to recruitment of SHP-1 and the inhibition of MAPK pathways and consequently T cell cytokine secretion. As a result, ligation of CEACAM1 in vivo results in inhibition of colitis in rheumatoid arthritis models. Characterization of the nonclassical major histocompatibility complex (MHC) class 1-related molecule, CD1. The oligoclonality of mucosal T cells led my laboratory to investigate nonpolymorphic MHC class I-related molecules such as CD1d and FcRn (see below) in mucosal tissues. We demonstrated that human and mouse CD1d is constitutively expressed by IECs with a unique biochemical structure and that CD1d on IECs functions in the polarized presentation of glycolipid antigens to T cells and is regulated in a novel manner by heat shock proteins. We showed such expression of CD1d and CD1d-restricted T cells in mucosal tissues to be regulated by Epstein Barr-Virus induced gene 3 and microsomal triglyceride transfer protein and directly linked these to the development of colitis and inhibition of mucosal colonization by bacteria in a variety of animal models in vivo. Characterization of the neonatal MHC class I-related Fc receptor (FcRn) for IgG. My laboratory challenged the dogma prevalent in the field that FcRn is expressed developmentally only during the neonatal period of life by showing that human FcRn is expressed in adults within IECs, dendritic cells and intestinal macrophages. We demonstrated that this expression is associated with the bidrectional transport of IgG across IECs, established some of the essential elements of the cell biologic itinerary associated with this transcytosis of IgG and proved that this pathway allows for the transport of antigen-IgG complexes into mucosal dendritic cells in vivo.
12
Richard S. Blumberg, M.D.
Teaching: I have been active in the training and mentoring of numerous residents and fellows in multiple clinical departments at the Brigham and Women’s Hospital and, as a Principal Investigator, I have directly mentored more than 50 undergraduate students, graduate students and post-doctoral fellows, many of whom have gone on to academic careers. At Harvard Medical School, I have been an active lecturer in many courses and serve on the Committee of Immunology. In the latter capacity, I have served as a Ph.D. thesis advisor on two occasions. I have also had numerous leadership roles in education including that as a course organizer for three major course offerings in Gastroenterology and Mucosal Immunology and am Chair for Education and Training for the AGA. I am the Principal Investigator of an Institutional Training Grant from the NIH, and I have served as the Program Director in Gastroenterology at BWH. In the latter capacity, I led the restructuring of this program leading to full accreditation by the ACGME.Clinical: As a clinician Board certified in Internal Medicine, Infectious Diseases and Gastroenterology, I have served over the years as consultant to the BWH, DFCI, BVAMC and MEEI. As a clinical leader, I briefly served as Acting Chief of the BVAMC and, since 1998, as the Chief of the Division of Gastroenterology, Hepatology and Endoscopy at the BWH. In the latter capacity, I was responsible for restructuring the Division leading to its recognition among the top ten Divisions in the nation by the U.S. News & World Report.
B. Research Funding Information:
NIH - Past: 1989-1992 NIH/Clinical Investigator Award PIAssembly and Function of the T cell receptor/CD3complex
1990-1992 NIH/P30 PI (pilot study)Molecular Characterization of IntraepithelialLymphocytes
1994-1996 NIH/P30 PI (pilot study)Molecular Characterization of the 34B1 AntigenicSystem
1996-1997 NIH/P30 PI (pilot study)Receptor-Mediated Transcytosis of IgG in Adult Life
1996-1997 NIH/P30 PI (pilot study)Antigen Recognition of T cells in IBD
1997-2002 NIH/RO1 Co-PI Function of Human Intestinal Lymphocytes
1999-2004 NIH/U39 Co-PIAutoimmunity: Treatment by Costimulatory Blockade
13
Richard S. Blumberg, M.D.
NIH Current: 1992-2015 NIH/M.E.R.I.T. PIMolecular Characterization of Mucosal Lymphocytes
1997-2011 NIH/RO1 PIRegulation of Mucosal Lymphocytes
1997-2011 NIH/R01 PIIntestinal Transcytosis of IgG in Adult Life
1999-2010 NIH/Center GrantCo-Director, Harvard Digestive Diseases Center
Other Past: 1991-1993 Crohn's & Colitis Foundation of America PI(The Carroll and Milton Petrie Research Award of
Excellence)Molecular Characterization of Human Intraepithelial Lymphocytes Associated with Inflammatory Bowel Disease
1995 Crohn's & Colitis Foundation of America PI Characterization of T Cell Clonal
Restriction inInflammatory Bowel Disease
1997-1999 Crohn's & Colitis Foundation of AmericaCharacterization of CD1d Function
1992-1993 Milton Fund PIMolecular Characterization of Intestinal Lymphocytes in Inflammatory Bowel Disease
1992-1994 Glaxo Research Institute PICharacterization of Intestinal Lymphocytes inInflammatory Bowel Disease
Other Present:
2005-2009 United States Israel Binational ScienceFoundation Co-PIThe Molecular Mechanism Controlling the
Interactions between Members of the CEACAM family and Immune Cells
2006-2009 Crohn’s and Colitis Foundation of America
14
Richard S. Blumberg, M.D.
Senior Research Award PI
Role of the unfolded protein response in colitis
Mentoring Grants - Past
2000-2003 Crohn’s & Colitis Foundation of AmericaCareer Development Award Mentor to
Xiaoping Zhu, D.V.M., Ph.D.
1999-2004 NIH/K08 Mentor to Hyun Sil Kim, M.D.Characterization of CD1d interacting proteins
1999-2004 NIH/K08 Mentor to Lawrence Saubermann, M.D.
Characterization of T cell receptor repertoireMentoring Grants – Current:
1996- NIH/T32 PreceptorInstitutional Training Grant, Combined Program in Pediatric Gastroenterology, Massachusetts General Hospital
1999-2010 NIH/T32 PI (Training Director)Institutional Training Grant, Gastroenterology Division, Brigham & Women's Hospital
1998-2008 NIH/T32 PreceptorInstitutional Training Grant, Department of Surgery, Brigham and Women’s Hospital
2006-2011 NIH/K08 Timothy Kuo, M.D.The Function of FcRn in the Liver and the Role of N-glycans.
C. Report of Current Research Activities:
Characterization of CD1d function in mucosal inflammation PIand intestinal epithelial cell-T cell interactions
Characterization of the cell biology and immunological function PIOf the neonatal Fc receptor (FcRn) in epithelia and macrophages
Characterization of the regulatory function of CEACAM1 in PIT cell biology and relationship to mucosal inflammation
15
Richard S. Blumberg, M.D.
D. Report of Teaching:
1. Local Contributions
a. Harvard Medical School, Boston, MA
1983-1986 Microbiology (Traditional Pathway)Laboratory instructor25-30 medical students60 hours/year
1990 Introduction to Clinical Medicine (HST program)Preceptor in physical examination2 medical students50 hours/year
1994-1996 Markey Biomedical Scientist Training ProgramLecturer, "Mucosal Immunology"12 graduate students15 hours/year
1996- Gastrointestinal Pathophysiology (HST program)Lecturer, "Mucosal Immunology"30 medical students15 hours/year
2001 Immunology and Microbiology (New Pathway)Group Leader for Case Presentation80 medical students5 hours/year
b. Graduate Medical Course
1997-1998 Developmental/Regional Immunology (IMM213)Lecturer, "Significance of Limited T Cell Repertoire at Mucosal Surfaces"15 graduate students15 hours/year
2000-2002 Introduction to Immunology (IMM201)Preceptor4-6 Graduate Students in Immunology Ph.D. Program20 hours/year
2001 Introduction to Immunology (IMM201)Discussion leader9 graduate students
16
Richard S. Blumberg, M.D.
8 hours/year
2002 - Immunology Seminar (IMM300)Discussion Leader10 graduate students12 hours/year
2004 - Introduction to Immunology (IMM202)Lecturer, “Mucosal Immunology I and II”15 graduate students10 hours/year
2004- Critical Reading for Immunology (IMM204)Discussion Leader10 graduate students10 hours/year
c. Local Invited Teaching Presentations
1992, 1996 Enteric Biology CourseLecturer, "Mucosal Immunology"80 fellows15 hours/year
1989 Morbidity and Mortality Weekly ConferenceDiscussant, "Gastric Outlet Obstruction"50 medical students, interns, residents and fellows10 hours/year
1996 Medical Grand Rounds, Department of MedicineLecturer, "Update on Inflammatory Bowel Disease: Pathogenesis
and its Relevance to Disease Therapy"10 hours/year
1999- Professors Rounds, General Medicine Service10 medical residents6 hours/year
2000 Medical Grand Rounds, Department of Medicine (VA BostonHealthCare System, West Roxbury Campus)Lecturer, “Update on Inflammatory Bowel Disease”10 hours/year
d. Continuing Medical Education Course
1989 Intensive Review of Internal Medicine, Department of Medicine
17
Richard S. Blumberg, M.D.
Lecturer, "The Gastrointestinal Manifestations of AIDS", "Infectious Enteritis", "Enteric Fever"100-400 CME students20 hours/year
1989-2002 Comprehensive Review of Gastroenterology,Lecturer, "The Gastrointestinal Manifestations of AIDS" and“The Hepatic Manifestations of AIDS”100-400 CME students12 hours/year
2002 Comprehensive Review of Gastroenterology,Lecturer, “How IBD Evolves – New Insights”100-400 CME students12 hours/year
2003- Housestaff Mentoring ProgramPhysician-Scientist in Internal Medicine training24 hours/year
e. Advisory and Supervisory Responsibilities in Clinical orLaboratory Setting
1990- Research laboratory advisor for predoctoral and postdoctoral (MD, PhD and MD/PhD college and graduate students)250 hours/year
1990- Attending Gastroenterology and Medicine for medical students, residents and fellows80 hours/year
1994 External Reviewer, Doctoral Thesis Committee, Department of Microbiology and Immunology, Mt. Sinai Medical School20 hours/year
1997- Ph.D. Thesis Advisory Committee (Lisa Steele), Graduate Program in Immunology, Harvard Medical School10 hours/year
2000-2002 Ph.D. Thesis Advisory Committee, Edward Nieuwenhuis, University of Utrecht, The Netherlands100 hours/year
1998-2003 Thesis Advisor for Steven Claypool, PhD Candidate in Immunology, Harvard Medical School100 hours/year
18
Richard S. Blumberg, M.D.
2004- Thesis Advisor for Stephanie Betz, Candidate in Immunology, Harvard Medical School100 years/year
f. Teaching Leadership Role
1998- Director of Fellowship Program in Gastroenterology,Brigham and Women’s HospitalFunction as program director for all administrative and educational activities related to ACGME-approved program for 15 fellows in Gastroenterology. Responsible for complete reorganization of program and full accreditation by residency review committee of the ACGME.
1999- Comprehensive Review of GastroenterologyCourse Co-DirectorFunction as Co-organizer of a CME course for 200-400 gastroenterologists together with Dr. Stephen Goldfinger (MGH), Dr. Daniel Podolsky (MGH) and Dr. Thomas Lamont (BIDMC). Together, we establish the curriculum and select the speakers.
2003 Gastroenterology for the Primary Care PhysicianCourse DirectorFunctioned as Co-organizer of a CME course for 100 primary care physicians with Dr. Sarath Reddy (BWH). Together, we chose all of the speakers and set the curriculum.
2003- Frontiers in Mucosal ImmunologyCourse DirectorEstablished a new course in Mucosal Immunity for active investigators in New England through the Harvard Digestive Diseases Center together with Dr. Nicholas Mantis (CHMC). We chose a steering committee, set the topics for discussion, picked the speakers and moderated the sessions.
g. Names of Advisees or Trainees
Years Name Present Position
1991-1992 Steven Burke, MD Sr. Vice President for Medical and Regulatory Affairs, Geltex, Inc., Waltham, MA
1990-1993 Stephen Landau, MDClinical Director, Millenium
Pharmaceuticals1993 Amal Al-Gawari, Ph.D. Sr.
19
Richard S. Blumberg, M.D.
Research Associate,
Millenium Pharmaceuticals1993-1995 Wilfredo Canchis, MD Assistant Professor, Cornell1994-1995 Tamara Koss Postdoctoral Research Fellow,
Boston Dermatology and Laser Center
1994-2001 Victor Morales, Ph.D.Postdoctoral Research
Fellow, Boston University Medical Center
1994-1996 Andreas Christ, MD Asst. Prof. of Medicine,University Hospital, Zurich
1994-1996 Christopher Probert, MD Assoc. Prof. of Medicine,Bristol Royal Infirmary, UK
1994-1996 Hyun Sil Kim, MD Asst. Prof. Medicine, UCSD1995 Jeffrey Encinas, PhD Sr. Scientist, Chugai
Pharmaceuticals1995-1996 Michael Teitell, MD, PhD Assoc. Prof. of Pathology, UCLA1995-1998 Lawrence Saubermann, M.D. Asst. Prof. of Medicine, Boston
University Medical Center1996-1998 K. Somnay- Asst. Prof. of Medicine, SUNY
Wadgoankar, MD Downstate1997 Lisa Steele
Investigator, Center for Disease Control
1997 Margot Furman Patent Attorney1997-1998 Relin Yang Medical Student, Univ. of Miami1997-2003 Xiaoping Zhu, DVM, PhD Assistant Professor, University
of Maryland1997-1999 Fumio Omata, MD Asst. Prof. of Medicine, Tokai
Medical College, Japan1998-2000 A. Nakajima, MD, PhD
Associate Professor and Chief of Gastroenterology, Yokohama City University Hospital, Japan
1998-2000 Sara Russell, MD Instructor in Surgery, BWH1998-2003 Steven Claypool, PhD
Postdoctoral Fellow, University of California, Los Angeles
1999-2000 Mark Ryan, PhD Senior Scientist, Nanomat, Ireland1999-2001 Richard Pitman, PhD Patent Attorney, London, UK2000-2001 Yvonne van de Wal, PhD Director, Clinical Laboratory,
Utrecht, The Netherlands2000-2002 Hideki Iijima, MD, PhD Assistant Professor, Osaka
20
Richard S. Blumberg, M.D.
University, Japan2000-2002 Edward Nieuwenhuis, MD Assistant Professor, University of
Rotterdam, The Netherlands2000-2002 R. Raychowdhury, PhD Instructor in Medicine, HMS2000-2002 Nadia Corazza, PhD Research Fellow, University of Bern2000-2006 T. Nagaishi, MD, PhD Assistant Professor of Medicine, Tokyo Medical & Dental
University, Tokyo, Japan2001-2005 Masaru Yoshida, MD, PhD Associate Professor of Medicine, Kobe University of Medicine,
Kobe, Japan2001 Markus Neurath, MD
Professor, University of Mainz, Germany
2002 JinYong Kim, MDAssistant Professor,
University of Korea2002-2004 Daohong Chen, MD, PhD Research Associate, BWH2002-2003 Suzana Sistig, DMD, Research Associate, University of
MD, PhD Louisville2003- Stephanie Dougan PhD Program in Immunology, HMS2003 Ewa Micewicz Research Fellow, DFCI2003-2004 Alicia Little Medical Student, Yale2003- Arthur Kaser, M.D., Ph.D. Research Fellow, BWH
2003-2004 Azucena Salas, Ph.D.Assistant Professor,
University of Barcelona2003- Timothy Kuo, M.D. Instructor in Medicine, HMS2003-2005 Flavio Rocha, M.D. Research Fellow, BWH2004-2006 Wael Haddad, M.D., Ph.D. Research Fellow, BWH2005 Bryan Vander Lugt PhD Program in Immunology, HMS
2005 Feilin ZhuSenior Research
Thesis, Harvard University2005- Kanna Kobayashi
Research Fellow, BWH2005- Zhangguo Chen
Research Associate, BWH2005- Shuo-Wang Qiao
Research Fellow, BWH
2006- Sebastian Zeissig Research Fellow, BWH2006- Lanfen Chen
Research Fellow,
21
Richard S. Blumberg, M.D.
BWH2007- Madelyn Ho Undergraduate Thesis Student,
Harvard University2007- Melanie Rhee Research Fellow, BWH
2. Regional, National, and International Contributions
1989 Invited speaker; "T cell receptor/CD3 complex structure and function"; Massachusetts General Hospital, Gastrointestinal Unit; Boston, MA
1991 Invited speaker; "Molecular characterization of intestinal intraepitheliallymphocytes"; Division of Gastroenterology, Boston University Schoolof Medicine; Boston, MA
Invited speaker; “Expression of CD1d by human gastrointestinal epithelial cells”; Digestive Diseases Week and the 92nd Annual Meeting of the American Gastroenterological Association; New Orleans, LA
Invited speaker; “T cell receptor (TCR-) expression and recognition of CD1 by a human jejunal intraepithelial lymphocyte (IEL) line”; Digestive Diseases Week and the 92nd Annual Meeting of the American Gastroenterological Association; New Orleans, LA
1992 Invited speaker; "Molecular characterization of mucosal T cellreceptor/CD1 interactions"; The Molecular and Cellular Basis of Inflammatory Bowel Disease Symposium, The Center for Gastrointestinal Biology and Disease; Chapel Hill, NC
Invited speaker; "CD1: a novel class I related molecule involved inintestinal epithelial cell - T cell interactions"; Conference on Intestinal Inflammation: Mechanisms and Modulation; Florence, Italy
Invited speaker; "Role of CD1 in human IEL-epithelial cell interactions"; Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Workshop on Intraepithelial Lymphocytes Boston, MA
Invited speaker; “Oligoclonal expansion of human lamina propria lymphocytes”; Digestive Diseases Week and the 93rd Annual Meeting of the American Gastroenterological Association; San Francisco, CA
Invited speaker; “Alternations of V usage in intraepithelial lymphocytes in inflammatory bowel disease”; Digestive Diseases Week and the 93rd
Annual Meeting of the American Gastroenterological Association; San Francisco, CA
Invited lecture; "Structure of CD1 on human intestinal epithelial cells"; Inflammatory Bowel Disease Center, University of Chicago Medical
22
Richard S. Blumberg, M.D.
School; Chicago, IL
1993 Invited lecture; "Molecular characterization of IEL - T cell interactions"; Graduate Program of Immunology, Tufts-New England Medical Center; Boston, MAInvited speaker; "Role of CD1 in human IEL-epithelial cell interactions"; FASEB Minisymposium on Antigen Presentation and Signal Transduction in the Mucosal Immune System; Denver, CO
Invited speaker; “Structure of CD1d on intestinal epithelial cells”; Digestive Diseases Week and the 94th Annual Meeting of the American Gastroenterological Association; Boston, MA
Invited speaker; “Expression of CD1a by altered human intestinal epithelium”; Digestive Diseases Week and the 94th Annual Meeting of the American Gastroenterological Association; Boston, MA
Invited lecture; "Role of CD1 in human IEL-epithelial cell interactions"; The Picower Institute for Medical Research, Cornell University Medical College; Manhasset, NY
Visiting Professor; "Role of CD1 in human IEL-epithelial cell interactions"; Gastroenterology Division, The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School; New Brunswick, NJ
1994 Invited speaker; "Role of nonclassical MHC class I molecules in intestinal epithelial cell-T cell interactions"; Digestive Diseases Week and the 94 th
Annual Meeting of the American Gastroenterological Association Annual Meeting, Minisymposium on Antigen Presentation in Intestine; New Orleans, LA
Invited speaker; “Cloning and characterization of a novel MHC class I associated ligand for T cells on human intestinal epithelial cells”; Digestive Diseases Week and the 94th Annual Meeting of the American Gastroenterological Association; Boston, MA
Invited speaker; "The new age of research in inflammatory bowel diseases: The role of non-classical MHC molecules in IEL function"; University of Chicago Inflammatory Bowel Disease Center; Chicago, IL
Invited speaker; "Novel MHC-like and associated molecules on intestinalepithelial cells"; Massachusetts General Hospital Immunology SeminarSeries, Boston, MA
Invited speaker; "Epithelial - T cell interactions in the intestine"; Division of Microbiol/Immunol; Mt. Sinai School of Medicine; New York, NY
23
Richard S. Blumberg, M.D.
Invited speaker; "Lymphoepithelial interactions in the human intestine"; Division of Immunology, Beth Israel Hospital; Boston, MA
1995 Invited speaker; "Receptors and ligands involved in lymphocyte-enterocyte interactions"; Keystone Symposium Conference on Mucosal Immunity:New Strategies for Protection Against Viral and BacterialPathogens; Keystone, CO
Plenary speaker; "Mucosal Immunology in IBD: The role of epithelialcells"; Falk International Symposium on Inflammatory Bowel Disease, Den Haag, Netherlands
Plenary speaker; "Novel MHC-like molecules on intestinal epithelial cells"; 8th International Conference on Mucosal Immunology; San Diego, CA
Invited speaker; "Intestinal epithelial - T cell interactions"; Department of Pathology, University of Connecticut Health Center; Farmington, CT
Invited speaker; “Biliary duct lymphocytes in primary sclerosing cholangitis (PSC) complicating ulcerative colitis are oligoclonal, T-cell receptor-+ cells”; Digestive Diseases Week and the 95th Annual Meeting of the American Gastroenterological Association; San Diego, CA
Invited speaker; “Chronic T cell clonal expansion in inflammatory bowel disease”; Digestive Diseases Week and the 95th Annual Meeting of the American Gastroenterological Association; San Diego, CA
Invited speaker; "Intestinal epithelial cell - T cell interactions"; Department of Gastroenterology, University of Texas Medical Branch at Galveston; Galveston, TX
Invited speaker; GRASP Center, New England Medical Center; "T cellreceptor repertoire in inflammatory bowel disease"; Boston, MA
1996 Invited speaker; "Characterization of T cell receptor repertoire in IBD"; Department of Gastroenterology, University of Colorado; Denver, CO
Invited speaker; "Characterization of T cell Receptor- Repertoire in IBD"; Department of Microbiology, Mount Sinai School of Medicine;
New York, NY
Invited speaker; "CD1 and other non classical HLA-molecules"; German Society for Immunogenetics; Leipzig, Germany
24
Richard S. Blumberg, M.D.
Visiting Professor; “Characterization of MHC class I-like molecules in mucosal immune function” and “Characterization of T-cell receptor repertoire in inflammatory bowel disease”; Gastroenterology Division, University of Virginia, School of Medicine; Charlottesville, VA
Invited speaker; "Characterization of T cell receptor repertoire in Inflammatory Bowel Disease"; Gastrointestinal Unit, Massachusetts General Hospital; Boston, MA
Invited speaker; “Functional major histocompatibility complex (MHC) class I-related Fc receptor expression in human adult enterocytes and intestinal epithelial cell (IEC) line”; Digestive Diseases Week and the 96th Annual Meeting of the American Gastroenterological Association; San Francisco, CA
Invited speaker; “Evidence for a T cell receptor chain motif in intestinal epithelium in ulcerative colitis (UC): a marker of severe disease?”; Digestive Diseases Week and the 96th Annual Meeting of the American Gastroenterological Association; San Francisco, CA
1997 Invited speaker; "The role of nonclassical MHC class I molecules in immune function"; Keystone Symposium on Mucosal Immunity: Cellular and Molecular Cross-Talk at Mucosal Surfaces; Santa Fe, NM
Visiting Professor; Gastroenterology Division, Northwestern University; Chicago, IL
Invited speaker; "Future approaches in the treatment of ulcerative colitis and Crohn's disease"; Boehringer-Ingelheim Pharmaceuticals, Inc.; Minisymposium; Ridgefield, CT
Invited speaker; “Transcellular transport of IgG across model human intestinal epithelial cells (IEC): potential role of the IgG-receptor, FcRn”;Digestive Diseases Week and the 97th Annual Meeting of the American Gastroenterological Association; Washington, DC
Invited speaker; “The pathogenesis of inflammatory bowel disease: the role of genetics, environment and inflammatory responses”; Indiana University, Indianapolis, IN
Invited speaker; "Diverse immunoglobulin superfamily members";
Annual Congress, British Society for Immunology; Brighton, UK
Invited speaker; "The pathogenesis of inflammatory bowel disease: the role of genetics, environment and inflammatory responses"; Ohio State University, Columbus, OH
25
Richard S. Blumberg, M.D.
Invited speaker; "MHC class I-related molecules on epithelial cells"; Center for the Study of Inflammatory Bowel Disease, Workshop on Intestinal Epithelium: Immune and Inflammatory Responses, Boston, MA
Invited speaker; "Lympho-epithelial cross-talk in mucosal immunobiology"; First Annual Immunology Retreat, Committee on Immunology, Harvard Medical School; Chatham, MA
1998 Invited teacher; Master Class on Mucosal Immunology; Utrecht, Holland.
Invited speaker; "Antigen uptake, presentation and epithelial cell biology";Falk Symposium on Induction and Modulation of GastrointestinalInflammation, Saarbrücken, Germany
Invited speaker; "Antigen Presentation"; Falk Symposium on Inflammatory Bowel Disease; Rostock, Germany
Visiting Professor; “Opportunistic infections of the GI tract” and “MHC-related Fc receptor in adult epithelia: characterization of a new paradigm”; Gastroenterology Division, University of Pennsylvania, Philadelphia, PA
Invited speaker; “The pathogenesis of inflammatory bowel disease: the role of genetics, environment and inflammatory responses”; University of Colorado, Denver, CO
Invited speaker; “Characterization of FcRn function in adult life”; University of Texas Southwestern Medical Center, Department of Microbiology and Immunology, Dallas, TX
Invited speaker; “Biliary glycoprotein (C-CAM) functions as a killer inhibitory receptor for human intestinal intraepithelial lymphocytes”; Immunology Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA
Invited speaker; “Involvement of human FcRn in adult intestinal epithelial cell transcytosis--a new paradigm?”; University of Florida, Gainesville, FL
Invited speaker; “Lymphocyte-epithelial cell cross-talk in the human intestine”; Center for Neurological Diseases, Brigham and Women’s Hospital, Boston, MA
Invited speaker; “Lymphocyte-epithelial cell interactions in the intestine”; Gastroenterology Unit, Massachusetts General Hospital, Boston, MA
Invited speaker; “CD1d biosynthetic pathway in a transfected T84 cell
26
Richard S. Blumberg, M.D.
line”; Digestive Diseases Week and the 98th Annual Meeting of the American Gastroenterological Association; New Orleans, LA
Invited speaker; “Biliary glycoprotein (BGP; CD66a) functions as an inhibitory co-receptor for activation of human intestinal intraepithelial lymphocytes (iIEL)”; Digestive Diseases Week and the 98th Annual Meeting of the American Gastroenterological Association; New Orleans, LA
Invited speaker; “Characterization of intestinal lymphocyte-epithelial cell interactions” and “Characterization of MHC class I-like molecules in intestinal epithelium”; International Meeting on Vaccines, Brazilian Society of Immunology, Salvador, Bahia, Brazil
Discussion leader; “Lymphocytes and IBD: current paradigms of disease mechanism and treatment”; Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, MA
1999 Invited speaker; “T cell-intestinal epithelial cell interactions”; Molecular Medicine of the Gut, Embo Workshop; Arolla, Switzerland.
Invited speaker; “BGP, a novel immunoregulatory molecule in the intestine”; New Strategies in IBD Therapy, Northwestern University, Chicago, IL
Invited speaker; “Characterization of CD1d in human intestinal epithelial cells”; Workshop on NK T cells and CD1 mediated antigen presentation; San Diego, CA
Invited speaker; “FcRn mediated transcytosis of IgG by human intestinal epithelial cells”; Membrane Biology Program, Brigham and Women’s Hospital, Boston, MA
Invited plenary speaker; “Antigen presentation by intestinal epithelial cells”; 10th International Congress of Mucosal Immunology (ICMI); Amsterdam, NL.
Invited speaker; “The pathogenesis of inflammatory bowel disease: the role of genetics, environment and inflammatory response”; University of Arizona, Phoenix, AZ.
Invited speaker; “Functional CD1d-mediated responses in intestinal epithelial cells; critical role of the cytoplasmic tail”; Digestive Diseases Week and the 99th Annual Meeting of the American Gastroenterological Association; New Orleans, LA
Invited speaker; “The pathogenesis of inflammatory bowel disease: the
27
Richard S. Blumberg, M.D.
role of genetics, environment and inflammatory response”; St. Louis Chapter of the Crohn’s & Colitis Foundation of America, St. Louis, MO.
Invited speaker; “Intestinal epithelial cell-T cell interactions”; Annual Meeting of the Chicago Chapter of the Crohn’s & Colitis Foundation of America, Chicago, IL.
2000 Invited speaker; “Role of CD1d in intestinal epithelial cell-lymphocyte interactions”; Keystone Symposia, Taos, NM.
Invited speaker; “One size fits all: the multiple roles of MHC class I-like molecules in epithelial cell function”; Department of Microbiology, Dartmouth Medical School, Hanover, NH
Invited speaker; “Immunologic functions of epithelial cells”; Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.
Invited speaker; “The pathogenesis of inflammatory bowel disease: the role of genetics, environment and inflammatory responses”; Rochester, NY
Invited speaker; “Lymphocyte-epithelial interactions in the intestine”; Department of Immunology, New York University, New York, NY
Invited speaker; “The utility of structure—the multiple roles of MHC class I-like molecules in epithelial cell function”; 12th Annual Symposium of the Japanese K-Club, San Diego, CA
Plenary speaker; “Natural killer (NK)-T cell activation by -Galactosylceramide in the presence of CD1d provides protection against colitis”; Digestive Diseases Week and the 100th Annual Meeting of the American Gastroenterological Association; San Diego, CA
Invited speaker; : “IBD immunology made easy”; Special Clinical Symposium on Inflammatory Bowel Disease, Digestive Diseases Week and the 100th Annual Meeting of the American Association of Gastroenterology, San Diego, CA.
Invited speaker; “Characterization of CD1d and NK-T cells in mucosal immunobiology”; Special Symposium – Immune Deviation and Tolerance in Autoimmune and Allergic Diseases, American Academy of Allergy, Asthma and Immunology, San Diego, CA
Invited speaker; “The pathogenesis of inflammatory bowel disease: The role of genetics, environment and inflammatory responses”; Oklahoma Chapter of the Crohn’s & Colitis Foundation of America, Tulsa, OK
28
Richard S. Blumberg, M.D.
Invited speaker; “Characterization of CD1d in mucosal immune Function: an immunotherapeutic target for inflammatory bowel disease?”;Department of Gastroenterology, Keio University, Tokyo, JapanInvited speaker; “Role of CD1d in intestinal epithelial cell-lymphocyteInteractions”; 4th US-Japan GI Meeting, Tokyo, Japan
Invited speaker; “The multiple roles of MHC class I-like molecules in mucosal immune function”; Asahikawa GI and Hepatology Symposium, Satellite Symposium of 4th US-Japan GI Meeting, Otaru, Hokkaido, JapanInvited speaker; “Function of CD1d in Intestinal Inflammation”;Department of Microbiology and Immunology, University of San Antonio, San Antonio, TX
Invited speaker; “Function of CD1d in Intestinal Inflammation”; Japanese Society of Immunology, Sendai, Japan
2001 Invited speaker; “The multiple roles of MHC class I-like molecules in mucosal immune function”; International Congress on Oral Immunology,Lillehammer, Norway.
Invited speaker: “The role of FcRn in transepithelial transport of IgGIn adult life”; University of Oslo, Oslo, Norway
Invited speaker; “Function of CD1d in mucosal inflammation”; Experimental Biology 2001, The American Society of Immunologists, Orlando, FL
Invited speaker; “Characterization of CD1d in the regulation of mucosal inflammation”; New England Medical Center, Boston, MA
Invited speaker; “Regulation of T lymphocyte function by CEACAM1”; Seminar Series, Harvard Institutes of Medicine, Boston, MA
Invited speaker; “Epithelial and T cell interactions in intestinal Inflammation”; 11th International Congress of Immunology, Stockholm,Sweden
Invited speaker; “Beyond tissue morphogenesis—T cell regulatory functions of CEACAM1”; Syntonix Pharmaceuticals, Waltham, MA
Invited speaker; “The immunoregulatory functions of CEACAM1 in Mouse T lymphocytes”; 12th Annual CEA Meeting, Providence, RI
Invited speaker; “Dysregulation of mucosal immunity for disease development”; International Meeting on Mucosal Immunology in the 21st
Century, Perdido Beach, Alabama
29
Richard S. Blumberg, M.D.
Visiting Professor; “The neonatal receptor for IgG (FcRn): not so neonatal”; Gastroenterology Division, University of Pittsburgh,Pittsburgh, PA
Invited speaker; “Immunological functions of the epithelium and its resident lymphoid cells”; Scuola Superiore d’Immunologia Ruggero Ceppellini School on Advances in Mucosal Immunity, Naples, Italy.
Invited speaker; “Human and mouse intestinal epithelial cells (IEC) present glycolipid antigens to natural killer (NK)-T cells in a CD1d-restricted manner”; Digestive Diseases Week and the 101st Annual Meeting of the American Gastroenterological Association, Atlanta, GA
Invited lecture; “From mystery to molecular: understanding the pathogenesis of Inflammatory Bowel Disease”; 15th Annual James A. Kangus Memorial Lecture, Pediatric Grand Rounds; Children’s Hospital of Pittsburgh, Pittsburgh, PA.
Invited speaker; “Immunoregulatory function of CEACAM1 on T lymphocytes”; Gastrointestinal Unit Research Seminar Series, Massachusetts General Hospital, Boston, MA
Invited Speaker; “Regulation of T lymphocyte function by CEACAM1”; Medical College of Ohio, Toledo, OH.
2002 Invited speaker: “Development of immunologic therapies directed at CEACAM1”; GenPat77, Berlin, Germany
Plenary speaker; “Immunological functions of polarized epithelia and IgG transport”; 11th International Congress of Immunology, Orlando, FL
Invited speaker; “Neonatal Fc-receptor for IgG – not so neonatal”; Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, MA
Plenary speaker; “Epstein-Barr Virus-induced gene 3 deficiency disrupts T helper 2-mediated immune responses in experimental colitis”; Digestive Diseases Week and the 102nd Annual Meeting of the American Gastroenterological Association San Francisco, CA
Invited speaker; “The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease”; Digestive Diseases Week and the 102nd Annual Meeting of the American Gastroenterological Association San Francisco, CA
Invited speaker; “Regulation of T cell-mediated, Hapten-induced murine colitis by CEACAM1”; Digestive Diseases Week and the 102nd Annual
30
Richard S. Blumberg, M.D.
Meeting of the American Gastroenterological Association San Francisco, CA
Invited speaker; “Impaired function of NK-T cells in EBI3-deficient animals”; Digestive Diseases Week and the 102nd Annual Meeting of the American Gastroenterological Association San Francisco, CA
Invited speaker; “Epstein-Barr Virus-induced gene 3 (EBI3) deficiency disrupts T helper 2-mediated immune responses”; Keystone Symposium on Microbial-Epithelial-Lymphocyte Interactions in Mucosal Immunity, Breckenridge, CO
Invited speaker; “Regulation of T lymphocyte functions by CEACAM1”; Department of Microbiology and Immunology, University of Colorado Health Sciences Center, Denver, CO
Invited speaker; “Epstein-Barr Virus-induced gene 3 (EBI3) deficiency disrupts T helper 2-mediated immune responses”; European Laboratory for the Investigation of Food-Induced Diseases, Naples, Italy.
Invited speaker; “Epstein-Barr Virus-induced gene 3 (EBI3) deficiency disrupts T helper 2-mediated immune responses”; Immunex/Wyeth Ayerst Industry Symposium, Second Federation of Clinical Immunology Society Meeting, San Francisco, CA
Invited speaker; “CD1d and microbial immunity”; Second International Workshop on CD1 and NKT Cells, Woods Hole, MA
Invited speaker; “Immunomodulatory properties of CEACAM1”; Retreat of the Program in Immunology, Harvard Medical School, Waterville Valley, NH.
2003 Visiting Professor; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Invited speaker; “FcRn-regulated transport of antibody and antibody-antigen immune complexes across intestinal epithelial cells”; Keystone Symposium on the Regulation of Mucosal Inflammation, Keystone, CO
Invited speaker; “Modulation of Th1 and Th2 cytokines in the therapy of inflammatory bowel disease”; Inflammation Research Association, Seattle, WA
Invited speaker; “Immunoregulatory functions of CD1d in mucosal tissues”; Major Symposium on “Mucosal Immunity: Guts and Glory” highlighting the top six investigators in mucosal immunology under the age of 50; American Association of Immunologists, Denver, CO
31
Richard S. Blumberg, M.D.
Invited speaker; “Modulation of Th2-modulated immune responses by EBI3”; International Falk Symposium on the Mechanisms of Intestinal Inflammation: Implications for Therapeutic Intervention in IBD”; Berlin, Germany
Invited speaker; “T cell regulatory functions of CEACAM1”; Division of Immunology, City of Hope, Duarte, CA
Invited speaker; “T cell regulatory functions of CEACAM1”; Mucosal Immunity Section, National Institutes of Health, Bethesda, MD
Invited speaker; “T cell regulatory functions of CEACAM1”; Boehringer-Ingelheim, Ridgefield, CT
Invited speaker; “Regulation and function of CD1d in intestinal epithelia”; University of Virginia Third Annual IBD Symposium, Charlottesville, VA
Invited speaker; “T cell regulatory functions of CEACAM1”; Symposium, Society of Mucosal Immunology, Paris, France
Invited speaker; “Regulation of IgG transport across intestinal epithelia by FcRn”; FOCIS meeting, Paris, France
Plenary speaker; “Specific regulation of T helper-1 mediated murine colitis by CEACAM1”; Annual meeting of the American Gastroenterological Association, Orlando, FL.
Invited speaker; “SHP-1 dependent and independent suppression of colitis by CEACAM1 isoform expressing a long cytoplasmic tail”; Annual meeting of the American Gastroenterological Association, Orlando, FL.
Invited speaker; “FcRn regulates transport of IgG and IgG/antigen complexes across mucosal epithelial barriers”; Annual meeting of the American Gastroenterological Association, Orlando, FL.
Invited speaker; “Intestinal lumen-derived heat-shock protein 110 regulates expression of MHC class I-like molecule CD1d on intestinal epithelial cells”; Annual meeting of the American Gastroenterological Association, Orlando, FL.
Key Note Address; “Mucosal T cells and their regulation in intestinal inflammation”; 30th Annual Meeting of the Japanese Society of Immunology, Tokyo, Japan
Invited speaker: “Regulation of mucosal T cells by CEACAM1”; Kyoto University Hospital, Kyoto, Japan
32
Richard S. Blumberg, M.D.
Invited speaker; “Regulation of T cell-mediated immune response by CEACAM1”; Society for Leukocyte Biology, Philadelphia, PAInvited speaker; “NKT cells in mucosal homeostasis”; New York Academy of Science, Second Workshop on Oral Tolerance, New York, NY
Invited speaker: “Neonatal Fc receptor-mediated transport of antigen-antibody complexes across epithelial barriers”; Jackson Laboratory, BarHarbor, ME
Invited speaker: “NK T cells in mucosal homeostasis”; Mt. Sinai School of Medicine, New York, NY
Invited speaker; “Specific regulation of T helper 1-mediated colitis by CEACAM1”; 14th Annual CEA Symposium, Munich, Germany
Invited speaker; “Modulation of Th1 and Th2 cytokines in the therapy of inflammatory bowel disease”; Crohn’s & Colitis Foundation of America, Houston, TX
Invited speaker; “Modulation of Th1 and Th2 cytokines in the therapy of inflammatory bowel disease”; Millenium Pharmaceuticals, Cambridge, MA
Invited speaker; “Regulation of IgG Transport Across Mucosal Barriers by FcRn”; British Society of Immunology, Harrogate, UK
Keynote speaker; “Research Advances in Human Inflammatory Bowel Disease”; Pediatric Inflammatory Bowel Disease Clinical Trials Workshop of the CCFA and NASPGHAN, Boston, MA
Invited speaker; “Specific regulation of T helper 1-mediated colitis by CEACAM1”; New England Regional Symposium on Frontiers in Mucosal Immunology, Boston, MA
Invited speaker; “Regulation of mucosal T cell-mediated immune responses by CEACAM1”; Section of Allergy and Clinical Immunology, Yale University, New Haven, CT
Invited speaker; “Regulation of T cell mediated immune responses by CEACAM1”; Society for Leukocyte Biology, Philadelphia, PA
Invited speaker; “Neonatal Fc receptor-mediated transport of antigen-antibody complexes across epithelial barriers”; Cedars Sinai Medical Center, Los Angeles, CA
33
Richard S. Blumberg, M.D.
2004 Invited speaker; “Regulation of CD1d function and CD1d-mediated inflammation by microsomal triglyceride transfer protein”; Bristol Myers Squibb, Princeton, NJ
Plenary speaker; “Microsomal triglyceride transfer protein regulates CD1d function”; American Gastroenterological Association, New Orleans, LA
Invited speaker; “Regulation of mucosal lymphocyte function byCEACAM1”; GI Unit, Massachusetts General Hospital, Boston, MA
Keynote speaker; “Neonatal Fc receptor-dependent transcytosis of IgG and IgG/antigen complexes across mucosal epithelial barrier”; Erasmus School of Molecular Medicine, Rotterdam, The Netherlands
Invited speaker; “Current concepts on the immunopathogenesis of IBD and their therapeutic implications”; St. Elizabeth’s Hospital, Boston, MA
Invited speaker and chair; “FcRn mediated regulation of immune-complex transport to mucosal dendritic cells”; Symposium on the function of epithelial cells in host defense and immune regulation, American Association of Immunologists, Washington, D.C.
Invited speaker and chair; “General overview of inflammatory mechanisms contributing to gut pathology”; 11th International Symposium on Celiac Disease, Belfast, Ireland
Invited speaker; “MTP regulation of CD1d function”; Center for Cardiovascular and Muscular Research, SUNY Downstate Medical Center, New York, NY
Invited speaker; “Regulation of CD1d function by microsomal triglyceride transfer protein”; Mucosal HIV and Immunobiology Center, University of Alabama, Birmingham, AL
Invited speaker; “The epithelial-lymphocyte-luminal interface”; European Society of Pediatric Gastroenterology, Hepatology and Nutrition, Capri, Italy
Invited speaker; “CEACAM1 regulation of mucosal T cell function”; 12th
International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Quebec, CanadaInvited speaker: “FcRn regulated transport of antigen-antibody complexes into mucosal dendritic cells”; Society of Mucosal Immunology Annual Meeting, Montreal, Quebec, Canada
Invited speaker; “Regulation of T helper 1 pathways in mucosal inflammation”; American Gastroenterological Association/British Society
34
Richard S. Blumberg, M.D.
of Gastroenterology, Oxford, UK
Invited speaker; “CD1d-microsomal triglyceride transfer protein interactions in mucosal immunity”; Third International Workshop on NKT Cells and CD1 mediated Antigen Presentation, Heron Island, Australia
Invited speaker; “Regulation of antigen transport across epithelial barriers mediated by neonatal Fc receptor”; Center for Immunology and Microbial Disease at the Albany Medical College, Albany, NY
Invited speaker; “Pathogenesis and diagnosis of ulcerative colitis”; Medica Sur Clinic & Foundation, Mexico City
Invited speaker; “Frontiers: inflammatory bowel disease: a blow to the gut”; Human Pathology Course, Harvard-MIT Division of Health Sciences and Technology, Boston, MA
Keynote speaker; “Case study of academia launched bio-venture: Co-opting the neonatal Fc receptor for drug delivery and beyond”; International Association for Biological and Medical Research, The Forsyth Institute and Tufts University School of Dental Medicine, Boston, MA
Invited speaker; “FcRn-mediated regulation of IgG antigen transport across mucosal barriers”; Mucosal Immunity Section, National Institutes of Health, Bethesda, MD
2005 Invited speaker; “Update on the pathogenesis of inflammatory bowel disease and therapeutic implications”; Medical Grand Rounds, VA Boston HealthCare System, West Roxbury, MA
Invited speaker; “The role of microsomal triglyceride transfer protein in CD1-restricted antigen presentation”; Immunobiology Division, Yale University, New Haven, CT
Invited speaker; “Regulation of colitis by carcinoembryonic antigen cell adhesion molecule 1”; Translational Medicine in Autoimmunity, Keystone Symposia, Big Sky, MT
Invited speaker: “Regulation of CD1d function by microsomal triglyceride transfer protein”; Immunology Seminar Series, Massachusetts General Hospital, Boston, MA
Invited speaker; “Lipids and IBD: Microsomal triglyceride transfer protein – the new dimension?”; Gut-Liver Interactions: Basic and Clinical Concepts, Falk Symposium, Innsbruck, Austria
35
Richard S. Blumberg, M.D.
Invited speaker: “SHP-1-dependent T cell inhibition by CEACAM1 isoforms expressed on a long cytoplasmic tail domain in vivo”; CEA Symposium, Berlin, Germany
Invited speaker; “Digestive protein, microsomal triglyceride transfer protein, directs lipids to the immune system”; 12th Symposium on Digestive Molecular Biology Research, Tokyo, Japan
Invited speaker: “Role of CEACAM1 as a regulator of T cells”; International Symposium on Inflammatory Bowel Disease – Research Drives Clinics, Münster, Germany.
Invited speaker: “SHP-1-dependent T cell inhibition by CEACAM1 isoforms expressing along cytoplasmic tail domain in vivo”; 13th Annual Conference of the International Cytokine Society, Seoul, Korea
Invited speaker: “Microsomal triglyceride transfer protein and CD1 function in mucosal immunity”; Gastroenterology Research Conference, The Johns Hopkins School of Medicine, Baltimore, MD
Invited speaker: “Regulatory pathways in IBD”; Fourth Annual Advances in the Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation of America, Miami Beach, FL
Invited speaker: “Neonatal Fc receptor for IgG: biology and therapeutic utility”; University of Pittsburgh Medical Center, Pittsburgh, PA
2006 Invited speaker: “Mucosal transport of IgG and of therapeutic proteins”; Medical Grand Rounds, Brigham and Women’s Hospital, Boston, MA
Invited speaker: “CD1d: at the cusp of innate and adaptive immunity in regulating intestinal inflammation”; International Symposium on Recent Advances in Inflammatory Bowel Disease, Tokyo, Japan
Invited speaker: “Mucosal transport of IgG and of therapeutic proteins”, Medical Grand Rounds, Northwestern Memorial Hospital, Chicago, IL
Invited speaker: “FcRn Regulation of Bacterial Responses”, Crohn’s and Colitis Foundation of America Microbial-Host Interactions Workshop, St. Petersburg, FL
Invited Speaker: “Regulation of CEACAM1 function ”, Emory University,Atlanta.
Invited Speaker: “Microsomal Triglceride transfer protein regulation of
36
Richard S. Blumberg, M.D.
CD1d”, University of Chicago, Chicago, IL Invited Speaker: “CEACAM1 mediates inhibition of arthritis”, AAI
Annual Meeting, Boston, MA Invited Speaker: “Lipid Antigen Presentation to Immune system in the
Gut and Liver: the role of MTP”, DDW, Los Angeles, CA Invited Speaker: “FcRn dependent IgG transport in mucosal immunity”,
Mini-Symposium in honor of Dr. Per Brandtzeg, Oslo, Norway
Invited Speaker: “Innate immune mechanisms in Inflammatory Bowel Disease”, Falk meeting, IBD: Mechanisms and Management, Moscow, Russia
Visiting Professor: “CEACAM1 regulation of lymphocyte function”, University of Pennsylvania, Philadelphia, PA
Invited Speaker: “CEACAM1 regulation of lymphocyte function”, Stanford University, CA
Invited Speaker: “CEACAM1 regulation of lymphocyte function”, SFB Symposium, Berlin, Germany
Keynote Speaker: “Regulation of Intestinal Epithelial Cell function by X- box binding protein – 1”, Frontiers in Mucosal Immunology, Boston, MA
Invited Speaker: “Regulation of CD1 by microsomal triglyceride transfer protein”, CD1/NKT Cell Conference, Siena, Italy
Invited Speaker: “CD1d: at the cusp of innate and adaptive immunity in regulating intestinal inflammation”, DDW Japan, Sapporo, Japan
Master Class: “Role of X-box binding protein 1 in regulation of colits”, Eijkman Seminar Series, Utrecht, The Netherlands
2007 Invited speaker: “Role of X-box binding protein 1 in regulation of colitis”, Japanese Society of Mucosal Immunology, Osaka, Japan
Invited speaker: “Role of X-box binding protein 1 in regulation of colitis”, Cedars Sinai Hospital, Los Angeles, CA
Invited Speaker: “XBP1 Links ER Stress of the Epithelium to Intestinal Inflammation”, 13th International Congress of Mucosal Immunology, Tokyo, Japan
37
Richard S. Blumberg, M.D.
Invited Speaker: “SHP-1-dependent, T cell inhibition by CEACAM1 isoforms expressing a long cytoplasmic tail domain.” 13 th International Congress of Immunology, Rio de Janeiro, Brazil
Visiting Professor: “The Role of FcRn in Antigen Presentation: Extending the Horizons of this IgG Receptor”, University of Texas Southwestern, Dallas, Texas
Invited Speaker: “Sequential Interaction of CEACAM1 with Lck and SHP-1 Downregulates TCR Signaling via Reduced ZAP-70 Activation”, 17th Annual CEA Symposium, Lake Arrowhead, CA
Invited Speaker: “SHP-1-dependent, T cell inhibition by CEACAM1isoforms expressing a long cytoplasmic tail domain”, II Falk Symposia and Workshop, Dresden, Germany
Invited Speaker: “ER Stress in the Intestinal Epithelium: A link to chronic inflammation and colon cancer development”, 4th Nestle International Nutrition Symposium, Lausanne, Switzerland
Invited Speaker: “Involvement of the ER Stress response in IBD”, GI Fellows’ Fall Retreat Seminar, Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital, Boston, MA
Keynote Speaker: “ER Stress of the Intestinal Epithelium and Inflammation”, Annual Meeting of the Israel Gastroenterological Association, Tiberias, Israel
3. Description of Teaching Awards
1995 Nominee, Harvard Medical School Award for Excellence in Mentoring
4. Major Curriculum Offerings
1998 Quarter Course in Immunology, Graduate Program in Immunology,Harvard Medical SchoolRichard S. Blumberg (Organizer)Catherine Nagler-Anderson (Co-Organizer)
E. Report of Clinical Activities:
I have conducted clinical activities as Associate Physician, Physician and Senior Physician at the Brigham and Women’s Hospital (BWH) since 1990, as an attending consultant in Gastroenterology and Internal Medicine. In these capacities, I am recognized for my expertise in inflammatory bowel diseases (IBD) and infectious diseases of the intestines and have provided consultation in these areas.
38
Richard S. Blumberg, M.D.
As Division Chief since 1998, I have been responsible for significant growth in the Gastroenterology, Hepatology and Endoscopy Division at the Brigham and Women’s Hospital. Specifically, I have been responsible for restructuring the Division with recruitment and appointment of more than 20 clinical and research faculty members at the BWH and 3 faculty members at the Boston Veteran’s Administration Medical Center (BVAMC), which included the recruitment of a Clinical Chief to the BWH and Chief of the Gastroenterology section at the BVAMC. I have also overseen the creation of a Digestive Health Center at the BWH. During this time, clinical and research activities of the Gastroenterology Division have grown significantly as manifest by an increase in clinical revenues from $1.5 to $7.5 million per year and the annual research base (clinical and basic research) from $4.8 to $32.5. This has led to increased recognition of the Division nationally as indicated by the recent ranking of the Gastroenterology Division as 10th in the United States in the 2006 edition of the U.S. News & World Reports.
My own basic research program has a strong translational component, which includes a total of a dozen issued and pending patents on the mucosal delivery of therapeutics and the treatment of a number of immunologically related diseases including IBD. In at least one case, my discoveries have been translated into human use through the successful completion of a human clinical trial by a regional biotechnology company involving the utility of targeting the neonatal Fc receptor for IgG for the transport of erythropoietin across the epithelial barriers of the human lung.
39
Richard S. Blumberg, M.D.
PART III: BIBLIOGRAPHY
Original Articles
1. Grindley JN, Blumberg R, Nakada D. Synthesis of R-Plasmid lactamase in minicells and in an in vitro system. J Bacteriol 1977;130:852-9.
2. Weniger BG, Blumberg RS, Campbell CL, Jones TC, Mount DL, Friedman SM. High level chloroquine resistance of plasmodium falciparum malaria acquired in Kenya. N Engl J Med 1982;307:1560-2.
3. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopath 1986;38:367-80.
4. Blumberg RS, Sandstrom EG, Paradis TJ, Neumeyer DN, Sarngadharan MG, Hartshorn KL, Byington RE, Hirsch MS, Schooley RT. Detection of human T-cell lymphotropic virus type III-related antigens and anti-human T-cell lymphotropic virus type III antibodies by anticomplementary immunofluorescence. J Clin Microbiol 1986;23:1072-7.
5. Hartshorn KL, Vogt MW, Chou TC, Blumberg RS, Byington R, Schooley RT, Hirsch MS. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant interferon alpha-A. Antimicrob Agents Chemother 1987;31:168-72.
6. Blumberg RS, Paradis T, Byington R, Henle W, Hirsch MS, Schooley RT. Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: Characterization of the cytotoxic response and lymphokine production. J Infect Dis 1987;155:877-90.
7. Blumberg RS, Paradis T, Crawford D, Byington R, Hirsch MS, Schooley RT. Effects of human immunodeficiency virus (HIV) on the cytotoxic response to Epstein-Barr virus (EBV) transformed B lymphocytes. AIDS Res Hum Retroviruses 1987;3:303-15.
8. Blumberg RS, Hartshorn KL, Ardman B, Kaplan J, Paradis T, Vogt M, Hirsch MS, Schooley RT. Dot immunobinding assay for detection of human immunodeficiency virus-associated antigens. J Clin Microbiol 1987;25:1989-92.
9. Blumberg RS, Paradis T, Hartshorn KL, Vogt M, Ho DD, Hirsch MS, Leban J, Sato VL, Schooley RT. Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. J Infect Dis 1987;156:878-84.
10. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno A, Blumberg RS, Kaplan J, Hirsch MS, Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-8.
11. Sancho J, Chatila T, Wong RCK, Hall C, Blumberg R, Alarcon B, Geha RS, Terhorst C. T-cell antigen receptor (TCR)-/ heterodimer formation is a prerequisite for association of CD3-2 into functionally competent TCR-CD3 complexes. J Biol Chem 1989;264:20760-9.
12. Reno TA, Ley S, Sugiyama E, Cantagrel A, Blumberg RS, Bonventre JV, Terhorst C, Yeh TH. Generalized defect in signal transduction caused by a T cell receptor chain substitution. Eur J Immunol 1990;20:1417-22.
40
Richard S. Blumberg, M.D.
13. Blumberg RS, Alarcon B, Sancho J, McDermott F, Lopez P, Breitmeyer J, Terhorst C. Assembly and function of the T cell antigen receptor: Requirement of either the lysine or arginine residues in the transmembrane region of the TCR- chain. J Biol Chem 1990;265:14036-43.
14. Blumberg RS, Ley SC, Sancho J, Lonberg N, Lacy E, McDermott F, Schad V, Greenstein JL, Terhorst C. Structure of the T cell antigen receptor: Evidence for two CD3- subunits in the T cell receptor/CD3 complex. Proc Natl Acad Sci USA 1990;87:7220-4.
15. Bleicher PA, Balk SP, Hagen SJ, Blumberg RS, Flotte TJ, Terhorst C. Expression of murine CD1 on gastrointestinal epithelium. Science 1990;250:679-82.
16. Blumberg RS, Sancho J, Ley SC, McDermott F, Tan KN, Breitmeyer J, Terhorst C. Genetic reconstitution of the T cell receptor- heterodimer restores the association of CD3-2 with the T cell receptor/CD3 complex. Eur J Immunol 1990;21:473-81.
17. Alarcon BA, Ley SC, Sanchez-Madrid F, Blumberg RS, Ju ST, Terhorst C. The CD3- and CD3- subunits of the T cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes. Embo J 1991;10:903-12.
18. Balk SP, Ebert EC, Blumenthal RV, Landau SB, Wucherpfennig KW, McDermott FV, Blumberg RS. Oligoclonality and recognition of CD1 by human intestinal intraepithelial lymphocytes. Science 1991;253:1411-15.
19. Blumberg RS, Terhorst C, Bleicher P, Allan C, MacDermott FV, Landau SB, Trier J, Balk SP. Expression of human CD1d on gastrointestinal epithelium. J Immunol 1991;147:2518-24.
20. Blumberg RS, Yockey C, Gross GG, Ebert EC, Balk SP. Clonally expanded human intestinal intraepithelial and lamina propria lymphocytes utilize multiple V T cell receptor genes. J Immunol 1993;150:5144-53.
21. Panja A, Blumberg RS, Balk SP, Mayer L. CD1d is involved in T cell:intestinal epithelial cell interactions. J Exp Med 1993;178:1115-9.
22. Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RS. Tissue distribution of the nonpolymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 1993;80:561-5.
23. Burke SB, Landau SB, Green R, Tseng CC, Nattakom T, Canchis W, Yang L, Gespach C, Kaiserlian D, Gespach C, Balk SP, Blumberg RS. Rat cluster of differentiation 1 molecule: expression on the surface of intestinal epithelial cells and hepatocytes. Gastroenterology 1994;106:1143-9.
24. Balk SP, Burke S, Polischuk JE, Frantz ME, Yang L, Porcelli S, Colgan SP, Blumberg RS. 2-microglobulin independent MHC class Ib molecule expressed by human intestinal epithelium. Science 1994;265:259-62.
25. Gross GG, Schwartz VL, Stevens C, Ebert EC, Blumberg RS, Balk SP. Diffuse distribution of intraepithelial lymphocyte clones in human intestinal mucosa. J Exp Med 1994;180:1337-44.
26. Brandeis JM, Sayegh, Gallon L, Blumberg RS, Carpenter CB. Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells.
41
Richard S. Blumberg, M.D.
Gastroenterology 1994;107:1537-42.
27. Blumberg RS, Koss T, Story C, Barasani D, Polischuk J, Lipin A, Pablo L, Green R, Simister N. A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 1995;95:2397-402.
28. Balk SP, Stevens C, Polischuk JE, Probert C, Ebert E, Terhorst C, Blumberg RS. Composition of T cell receptor/CD3 complex in human intestinal intraepithelial lymphocytes: lack of FcRI chain. Int Immunol 1995;7:1237-1241.
29. Kim H, Morales V, Teitell M, Encinas J, Blumberg R. Cloning of the gene encoding the mouse homologue of the human calcium signal-modulating ligand. Gene 1995;163:323-4.
30. Chott A, Gross GG, Probert C, Schwartz VL, Blumberg RS, Balk SP. Analysis of T cell antigen receptor expression by intestinal mucosa lymphocytes demonstrates a common junctional motif among CD8+ T cells in ulcerative colitis. J Immunol 1996a; 156:3024-3035.
31. Taplin ME, Frantz M, Canning C, Blumberg RS, Balk SP. Evidence against extrathymic T cell maturation in the adult human intestine based upon lack of terminal deoxynucleotidyl-transferase expression. Immunology 1996;87:402-7.
32. Colgan SP, Balk SP, McGuirk D, Landau SL, Madara JL, Blumberg RS. Interferon- modulates CD1d surface expression on intestinal epithelia. Am J Physiol (Cell Physiol) 1996;271:C276-83.
33. Landau SB, Probert CS, Stevens AC, Balk SP, Blumberg RS. Over-utilization of J3 gene segment in Crohn's colitis. J Clin Lab Immunol 1996;48:33-44.
34. Probert CS, Chott A, Turner JR, Bodinaku K, Elson CO, Balk SP, Blumberg RS. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol 1996b;157:3182-91.
35. Probert CS, Christ AD, Saubermann LJ, Turner JR, Chott A, Carr-Locke D, Balk SP, Blumberg RS. Analysis of human common bile duct associated T cells: evidence for oligoclonality, T cell clonal persistence and epithelial cell recognition. J Immunol 1997; 158:1941-48.
36. Christ AD, Colgan SP, Balk SP, Blumberg RS. Human intestinal epithelial cell lines produce factor(s) that inhibit CD3-mediated T-lymphocyte proliferation. Immunol Lett 1997;58:159-65.
37. Koningsberger JC, Chott A, Logtenberg T, Wiegman L, Blumberg RS, Henegouwen GP, Balk SP. T cell development in human intestine and identification of an early T cell receptor chain transcript. J Immunol 1997;159:1775-82.
38. Chott A, Gerdes D, Ebert E, Spooner A, Mosberger I, Kummer JA, Blumberg RS, Balk SP. Intraepithelial lymphocytes in normal human intestine do not express proteins associated with cytolytic function. Am J Pathol 1997;151:435-42.
39. Israel EJ, Taylor S, Mizoguchi E, Blumberg RS, Bhan A, Simister NE. Expression of the major histocompatibility complex class I-like Fc receptor for IgG on the human intestinal epithelial cell. Immunology 1997;92:69-74.
42
Richard S. Blumberg, M.D.
40. Christ AD, Stevens AC, Koepper H, Devergne O, Birkenbach M, Blumberg RS. Epstein-Barr virus induced gene 3, a novel, interleukin-12 related cytokine, is expressed in human intestine and upregulated in ulcerative colitis but not in Crohn's disease. Gastroenterology 1998; 115:307-13.
41. Anumanthan A, Bensussan A, Boumsell L, Christ A, Blumberg RS, Voss S, Robertson MJ, Nadler L, Freeman GJ. Cloning and characterization of BY55, an NK and cytolytic T lymphocyte specific cell surface glycoprotein. J Immunol 1998;161:2780-90.
42. Utku N, Heinemann T, Tullius S, Bulwin G-C, Beinke S, Blumberg RS, Beato F, Randall J, Kojima R, Busconi L, Robertson ES, Schülein R, Volk H-D, Milford EL, Gullans SR. Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 1998;9:509-18.
43. Kim H, Garcia J, Exley M, Porcelli S, Balk SP, Blumberg RS. Biochemical characterization of CD1d expression in the absence of 2-microglobulin. J Biol Chem 1999;274:9289-95.
44. Saubermann LJ, Probert CS, Chott A, Balk SP, Blumberg RS. Evidence of T cell receptor -chain patterns in inflammatory and noninflammatory bowel disease states. Am J Physiol 1999;G613-21.
45. Somnay-Wadgaonkar K, Nusrat A, Kim HS, Canchis WP, Campbell N, Mayer LM, Balk SP, Colgan SP, Blumberg RS. Immunolocalization of CD1d in human intestinal epithelial cells and identification of a 2-microglobulin associated form. Int Immunol 1999;383-92.
46. Panczak A, Hirsch F, Blanpied C, Hagerty D, Polischuk, Blumberg R, Druet P, Poncet P. The new anti-L cell 4D4 monoclonal antibody defines an activation marker-related molecule also present on CD8+ T cells, on peritoneal B cells and on renal, pulmonary and intestinal epithelia. Folia Biologica (Praha) 1999;45;101-114.
47. Campbell NA, Blumberg RS, Balk S, Mayer L. The novel CD8 ligand, gp180, coassociates with CD1d in intestinal epithelial cells. J Biol Chem 1999;274:26259-65.
48. Morales V, Christ A, Watt S, Kim H-S, Johnson KW, Utku N, Texieira AM, Mizoguchi A, Mizoguchi E, Russell G, Bhan AK, Freeman G, Blumberg R. Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol 1999;163:1363-70.
49. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS§, Lencer WI. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999;104:903-11. (§Co-Corresponding Author)
50. Colgan SP, Hershberg RM, Furuta GT, Blumberg RS. Ligation of epithelial CD1d by antibody crosslinking induces bioactive IL-10; critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci USA 1999;96:13938-43.
51. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SMA, Patton KT, Blumberg RS, Porcelli S, Chott A, Balk SP. Development and activation regulated expression of CD1d in human lymphoid and myeloid lineages. Immunology 2000;100:37-47.
43
Richard S. Blumberg, M.D.
52. Mühlhöfer A, Saubermann L, Gu X, Blumberg RS, Xavier R, Podolsky DK, MacDermott RP, Reinecker H-C. Fractalkine is an epithelial and endothelial cell derived chemoattractant for intraepithelial lymphocyte in the small intestinal mucosa. J Immunol 2000;164:3368-76.
53. Badizadegan K, Dickinson BL, Wheeler HE, Blumberg RS, Lencer WI. Heterogeneity of detergent insoluble membranes from human intestinal epithelia containing caveolin-1 and ganglioside GM1. Am J Physiol (Gastrointest Liver Physiol) 2000;278:G895-G904.
54. Saubermann LJ, Beck P, de Jong YP, Pitman RS, Ryan M, Exley M, Snapper S, Balk SP, Kanauchi O, Motoki K, Hagen SJ, Terhorst C, Podolsky DK, Koezuka Y, Blumberg RS. Natural killer-T cells activated by -galactosylceramide in the presence of CD1d provide protection against colitis in mice. Gastroenterology 2000;119:119-28.
55. Wei Y, Mrsny RJ, Blumberg RS, Fried M, Christ AD. Choice of microcentrifuge tubes influences T cell proliferation assays. BioTechniques 2000;29:54-9.
56. Mizoguchi A, Mizoguchi E, Saubermann LJ, Higaki K, Blumberg RS, Bhan AK. Limited CD4+ T cell diversity associated with colitis in T cell receptor mutant mice requires a T helper 2 environment. Gastroenterology 2000;119:983-95.
57. Roberts AI, Blumberg R, Christ AD, Ebert EC. Staphylococcal enterotoxin B induces potent cytotoxic activity by intraepithelial lymphocytes. Immunology 2000;101:185-90.
58. Kim HS, Colgan S, Pitman R, Hershberg R, Blumberg RS. Human CD1d associates with prolyl-4-hydroxylase during its biosynthesis. Mol Immunol 2000;37:861-8.
59. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS§, Nagai R, Matsuhashi N. Endogenous PPAR mediates anti-inflammatory activity in a model of ischemia-reperfusion injury. Gastroenterology 2001;120:460-9. (§Corresponding author)
60. Zhu X, Meng G, Dickinson BL, Li X, Mizogushi E, Robert C, Miao L, Wang Y, Claypool S, Wu B, Smith PD, Lencer WI, Blumberg RS. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, macrophages and dendritic cells. J Immunol 2001;166:3266-76.
61. Probert CS, Saubermann LJ, Stevens AC, Balk SP, Blumberg RS, Chott A. Prevalence of an ulcerative colitis associated CD8+ T cell receptor -chain CDR3 region motif and its association with disease activity. J Clin Immunol 2001,12:126-34.
62. Omata F, Christ A, Birkenbach M, Blumberg RS. The expression of IL-12 p40 and its homologue, Epstein-Barr induced gene 3, in inflammatory bowel disease. Inflammatory Bowel Dis 2001;7:215-20.
63. Watt SM, Teixeira AM, Doyonnas R, Grunert F, Kuroki M, Blumberg RS, Bates PJ. Homophilic adhesion of human CD66a/biliary glycoprotein involves N-terminal domain interactions: structural analysis of the binding site. Blood 2001;98:1469-79.
64. Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of adenovirus expressing IL-18 antisense mRNA. J Immunol 2002;168:411-20.
44
Richard S. Blumberg, M.D.
65. Nakajima A, Iijima H, Neurath MF, Nagaishi T, Nieuwenhuis EES, Raychowdhury R, Glickman J, Blau DM, Russell S, Holmes KV, Blumberg RS. Activation-induced expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates mouse T lymphocyte function. J Immunol 2002;168:1028-35.
66. Mizoguchi A, Mizoguchi E,Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10 producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002;16:219-30.
67. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002;168:2803-10.
68. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Galle PR, Bhan A, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS. The transcription factor t-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 2002;195:1129-43.
69. Nieuwenhuis EES, Matsumoto T, Exley M, Schleipman R, Glickman J, Corazza N, Colgan S, Onderdonk A, Blumberg RS. CD1d-dependent, macrophage-mediated clearance of Pseudomonas aeruginosa from the lungs. Nature Med 2002;8:588-93 (Editorial Commentary, Nature Immunology 2002;3:513
70. Claypool SM, Dickinson BL, Lencer WI, Blumberg RS. Biogenesis, distribution and function of the human neonatal Fc receptor in MDCK cells is modified by human 2m. J Biol Chem 2002;277:28038-50.
71. Spiekermann GM, Finn PW, Dumont J, Blumberg RS, Lencer WI. Receptor-mediated IgG transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung. J Exp Med 2002;196:281-92.
72. Zhu X, Peng J, Miao L, Raychowdhury R, Nakajima A, Lencer WI, Blumberg RS. The heavy chain of Fc receptor for IgG is sequestered in endoplasmic reticulum by forming oligomers in the absence of 2-microglobulin association. Biochem J 2002;367:703-14.
73. Saubermann LJ, Nakajima A, Wada K, Zhao S, Matsuhashi N, Nagai R, Blumberg RS. PPAR agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflammatory Bowel Dis 2002;8:330-9.
74. Perez A, Grikscheit TC, Blumberg RS, Ashley SW, Vacanti JP, Whang EE. Tissue-engineered small intestine: ontogeny of the immune system. Transplantation 2002;74:619-23.
75. Heller F, Fuss IJ, Nieuwenhuis E, Udey M, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13- producing NK-T cell. Immunity 2002;17:619-38.
76. Nieuwenhuis EES, Neurath MF, Corazza N, Iijima H, Trgovcich J, Wirtz S, Glickman J, Bailey D, Yoshida M, Galle PR, Kronenberg M, Birkenbach M, Blumberg RS. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-
45
Richard S. Blumberg, M.D.
deficient mice. Proc Natl Acad Sci USA 2002;99:16951-6.
77. Shah U, Dickinson BL, Blumberg RS, Simister NE, Lencer WI, Walker WA. The distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatric Res 2003;53:295-301.
78. van de Wal Y, Corazza N, Ryan M, Hershberg R, Koezuka Y, Colgan S, Blumberg RS. Delineation of a CD1d-restricted antigen presentation pathway associated with intestinal epithelial cells. Gastroenterology 2003;124:1420-31.
79. Katayama K, Wada K, Nakajima A, Yoshida S, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki, Nagai R, Kamisaki Y, Blumberg RS§, Mayumi T. A novel PPAR-gene therapy approach to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003;124:1315-24. (§Corresponding author).
80. Tiede I, Wirtz S, Strand D, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Lehr HA, Iven H, Blumberg R, Walczak H, Galle PR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes: A mechanism for azathioprine-mediated immunosuppression in Crohn’s disease based on the induction of T cell apoptosis. J Clin Invest 2003;111:1133-45.
81. Colgan SP, Pitman RS, Nagaishi T, Mizoguchi A, Mizoguchi E, Mayer L, Sartor, BR, Subjek JR, Blumberg RS. Intestinal lumen-derived heat shock protein 110 regulates expression of the MHC-Class I-like molecule CD1d on intestinal epithelial cells. J Clin Invest 2003;112:745-54 (Editorial Commentary, J Clin Invest 2003;112:464-48; Editorial Commentary, Nature Rev Immunol 2003;3:778).
82. Gillessen S, Naumov YN, Nieuwenhuis EES, Exley MA, Lee FS, Mach N, Luster AD, Blumberg RS, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Wilson SB. CD1d-restricted T cells regulate dendritic cell function and anti-tumor immunity in a GM-CSF-dependent fashion. Proc Natl Acad Sci USA 2003;112:745-54.
83. Matsumoto T, Nieuwenhuis EES, Cisneros RL, Ruiz B, Blumberg RS, Onderdonk AB. Protective effect of ethyl-e-)3-dimethyl aminopropyl) urea dihydrochloride (EDU) against lipopolysaccharide-induced death in mice. J Med Microbiol 2004;53:97-102.
84. Kumamoto Y, Tomschegg A, Bennai-Sanfourche F, Schweizer A, Boerner A, Hoffmann A, Blumberg RS, Volk H-D, Utku N. Induction therapy with monoclonal antibody specific for TIRC7 significantly delays rejection of cardiac allograft in mice. Am J Transplant 2004;4:505-14.
85. Markel G, Massaffi H, Ling K-L, Salio M, Gadola S, Steuer G, Blau H, Achdout H, de Miguel M, Gonen-Gross T, Zimron U, Volkovich I, Eisenbach L, Blumberg RS, Porgador A, Cerundolo V, Mandelboim O. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients: Blood 2004;103:1770-8.
86. Chen D, Iijima H, Nagaishi T, Nakajima A, Russell S, Yoshida M, Raychowdhury R, Morales V, Rudd CE, Utku N, Blumberg RS. CEACAM1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol 2004;172:3535-43.
87. Iijima H, Neurath M, Nagaishi T, Glickman JN, Nieuwenhuis EES, Nakajima A, Fuss IJ, Utku N, Lewicki DN, Gallagher TM, Holmes KV, Blumberg RS. Specific regulation of T helper 1-mediated murine colitis by CEACAM1. J Exp Med 2004;199:471-82.
46
Richard S. Blumberg, M.D.
88. Claypool SM, Dickinson BL, Venugoplan N, Wagner JS, Johansen F-E, Bailey DT, Borawski JA, Lencer WI, Blumberg RS. Bi-directional transepithelial IgG transport by a strongly polarized basolateral membrane Fc receptor. Mol Biol Cell 2004;15:1746-59.
89. Brozovic S, Nagaishi T, Yoshida M, Betz S, Salas A, Chen D, Kaser A, Glickman J, Little A, Corazza N, Kim JY, Colgan SP, Young SG, Exley M, Blumberg RS. CD1d function is regulated by microsomal triglyceride transfer protein. Nature Med 2004;10:535-9.
90. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang J, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Non-classical CD1d-restricted NKT cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
91. Hokama A, Mizoguchi E, Tanaka Y, Yoshida M, Rietdijk ST, de John YP, Terhorst C, Snapper SB, Litman DR, Blumberg RS, Mizoguchi A. Identification of an epithelial lectin that possesses immunogenic activity under intestinal inflammatory conditions. Immunity 2004;20:681-93.
92. Yoshida M, Claypool SM, Mizoguchi E, Mizoguchi A, Roopenian DC, Lencer W, Blumberg, RS. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens into mucosal dendritic cells. Immunity 2004;20:769-83.
93. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp K, Palombella VJ, Sattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS. Pulmonary delivery of a novel erythropoietin Fc-fusion protein in non-human primates using an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101:9763-8.
94. Utku N, Boerner A, Tomschegg A, Bennai-Sanfourche F, Bulwin G-C, Heinemann T, Loehler J, Blumberg RS, Volk H-D. TIRC7 deficiency causes in vitro augmentation of T and B cell activation and cytokine response. J Immunol 2004;173:2342-2352.
95. Wada K, Nakajima A, Takahashi H, Yoneda M, Fujisawa N, Ohsawa E, Kadowaki T, Kubota N, Terauchi Y, Matsuhashi N, Saubermann LJ, Nakajima N, Blumberg RS. Pro-tective effect of endogenous PPAR against acute gastric mucosal lesions associated with ischemia-reperfusion. Am J Physiol 2004;287:G452-8.
96. Markel G, Achjdout H, Katz G, Ling K-L, Salio M, Gruda R, Gazit R, Mizrahi S, Hanna J, Gonen-Gross T, Arnon TI, Lieberman N, Stren N, Nachmias B, Blumberg RS, Steuer G, Blau H, Cerundolo V, Mussaffi H, Mandelboim O. Biological function of the soluble CEACAM1 and the implications in TAP-2 deficient patients. Eur J Immunol 2004;34:2138-48.
97. Markel G, Gruda R, Achdout H, Katz G, Nechama M, Blumberg RS, Kammerer R, Zimmermann W, Mandelboim O. The critical role of residues R43 and Q44 of CEACAM1 in the protection from killing by human NK cells. J Immunol 2004;173:3732-9.
47
Richard S. Blumberg, M.D.
98. Anfossi N, Robbins SH, Ugolini S, Georgel P, Hoebe K, Bouneaud C, Ronet C, Kaser A, DiCioccio CB, Tomasello E, Blumberg RS, Beutler B, Reiner S, Alexopoulou L, Lantz O, Raulet DH, Brossay L, Vivier E. Expansion and function of CD8+ T cells expressing Ly49 inhibitory receptors specific for MHC class I molecules. J Immunol 2004;173:3773-82.
99. Yoneda M, Wada K, Katayama K, Nakajima N. Iwasaki T, Osawa E, Mukasa K, Yamada Y, Blumberg RS, Sekihara H, Nakajima A. A novel therapy for acute hepatitis utilizing dehydroepiandrosterone in the murine model of hepatitis. Biochem Pharmacol 2004;68:2283-9.
100. Nieuwenhuis E, Gilessen S, Scheper R, Exley M, Taniguchi M, Dranoff G, Blumberg R§, Wilson SB. CD1d and CD1d restricted iNKT cells play a pivotal role in contact hypersensitivity. Exp Dermatol 2005;14:250-8. (§Co-senior author)
101. Stirling CMA, Charleston B, Takamatsu H, Claypool S, Lencer W, Blumberg RS, Wile-man TE. Characterisation of the porcine neonatal Fc receptor: potential use for trans-ep-ithelial protein delivery. Immunology 2005;114:542-3.
102. Wirtz S, Becker C, Fantini M, Nieuwenhuis EES, Tubbe I, Galle PR, Schild HJ, Birkenbach M, Blumberg RS, Neurath M. Epstein-Barr virus-induced gene 3 (EBI3) transcription is induced by TLR signaling in primary dendritic cells (DC) via NFB activation. J Immunol 2005;174:2814-24.
103. Blumberg RS, Pitman RS, Taylor CT, Colgan SP. Cholera toxin potentiates influences of interferon- through activation of NFB and release of tumor necrosis factor-. J Interferon Cytokine Res 2005;25:209-19.
104. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS§, Serhan CN. Resolvin E1, a novel endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against TNBS-induced colitis. Proc Natl Acad Sci 2005;102:7671-6. (§Co-senior author)
105. Zahn S, Wirtz S, Birkenbach M, Blumberg RS, Neurath MF, von Stebut E. Impaired Th1 responses in mice deficient in Epstein-Barr virus-induced gene 3 and challenged with physiological doses of Leishmania major. Eur J Immunol 2005;35:1106-12.
106. Zhu X, Peng J, Chen D, Liu X, Ye L, Iijima H, Kadaval K, Lencer WI, Blumberg RS. Calnexin and ERp57 facilitate the assembly of the neonatal Fc receptor for IgG with 2-microglobulin in the endoplasmic reticulum. J Immunol 2005;175:967-76.
107. Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, Morrison J, Khurana A, Kronen-berg M, Johnson C, Exley M, Hussain MM, Blumberg RS. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen presenting cells. J Exp Med 2005;202:529-39.
108. Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, Kakimi K. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCRF3 by a nonpeptide chemokine receptor antagonist protects mice from Dextran Sodium Sulfate-mediated colitis. Int Immunol 2005;17:1023-34.
48
Richard S. Blumberg, M.D.
109. Furuta GT, Nieuwenhuis EES, Karhausen J, Gleich G, Blumberg RS, Lee J, Ackerman SJ. Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J Physiol (Gastrointest Liver Physiol) 2005;289:G890-7.
110. Leav BA, Woodman B, Rogers KA, Yoshida M, Blumberg RS, Ward HD. An early mucosal source of interferon- is associated with resistance to an control of Cryptosporidium parvum infection in mice. Infect Immun 2005;73:8425-8.
111. Brozovic S, Sahoo R, Barve S. Shiba H, Uriarte S, Blumberg R, Kinane D. Porphyromonas gingivali enhances FasL expression via up-regulation of NFB-mediated gene transcription and induces apoptotic cell death in human gingival epithelial cells. Microbiology 2006; 152: 797- 806.
112. Utku N, Heinemann T, Winter M, Bulwin CG, Schlawinsky M, Fraser P, Nieuwenhuis EES, Volk H-D, Blumberg RS. Monoclonal antibody targeting of TIRC7 results in significant therapeutic effects on T and B cell response in collagen-induced arthritis in mice. Clin Exp Immunol 2006; 144:142-51.
113. Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, Kubota N, Terauchi Y, Tachibana M, Miyoshi H, Kamisaki Y, Mayumi T, Kadowaki T, Blumberg RS. Peroxisome proliferator-activated receptor gamma –mediated regulation of neural stem cell proliferation and. J Biol Chem. 2006;281:12673-81.
114. Yoshida M, Kobayshi K, Kuo T, Bry L, Glickman J, Claypool SM, Kaser A, Nagaishi T, Higgins D, Mizoguchi E, Wakatsuki Y, Roopenian D, Mizoguchi A, Lencer, WI Blumberg RS. Neonatal Fc receptor for IgG regulates mucosal immune response to luminal bacteria. J Clin Invest;116:2142-5.
115. Nagaishi T, Pao L, Iijima H, Chen D, Glickman J, Nakajima A, Neel BG, Blumberg RS. SHP1 dependent T cell inhibition by CEACAM1 isoforms expressing a long cytoplasmic domain. Immunity 2006;116:2142-51.
116. Wirtz S, Tubbe I, Birkenbach M, Galle P, Blumberg R, Neurath M. Protection from lethal septic shock by neutralizing the biological function of Interleukin-27. J Exp Med. 2006;203:1875-81.
117. Bulwin GC, Heinemann T, Bugge V, Winter M, Lohan A, Schlawinsky, M, Schulze A, Sabat R, Schulein R, Wienes B, Blumberg R, Volk H-D, Utku, N. TIRC7 inhibits T cell proliferation of modulation of CTLA-4 expression. J Immunol 2006;77:6833-41.
118. Markel G, Seidman R, Stern, N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Lowenthal R, Mandelboim O, Orenstein A, Schachter J. Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions. J Immunol 2006;177:6062-7
119. Perera L, Shao L, Patel A, Evans K, Meresse B, Blumberg RS, Geraghty D, Groh V, Spies T, Jabri B, Mayer L. Expression of non-classical molecules by intestinal epithelial cells. Inflammatory Bowel Dis 2007;13:298-307.
120. Dougan SK, Rava P, Hussain MM, Blumberg RS. MTP regulated by an alternate promoter is essential for NKT cell development. J Exp Med 2007;204:533-545.
121. Kawana K, Quayle AJ, Ficarra M, Ibana, JA, Shen L, Kawana Y, Yang H, Marrero L, Yavagal S, Greene SJ, Zhang YX, Pyles RB, Blumberg RS, Schust DJ. CD1d degrada-
49
Richard S. Blumberg, M.D.
tion in Chlamydia trachomatis-infected epithelial cells is the result of both cellular and chlamydial proteasomal activity. J. Biol Chem 2007;282:7368-75.
122. Hausding M, Karwot R, Scholtes P, Lehr HA, Wegmann M, Renz H, Galle PR, Birkenbach M, Neurath MF, Blumberg RS, Finotto S. Lung CD11c(+) cells from mice deficient in Epstein-Barr virus-induced gene 3 (EBI-3) prevent airway hyper-responsiveness in experimental asthma. Eur J Immunol 2007;37:1663-1667.
123. Mizoguchi A, Ogawa A, Takedatsu H, Sugimoto K, Shimomura Y, Shirane K, Nagahama K, Nagaishi T, Mizoguchi E, Blumberg RS, Bhan AK. Dependence of intestinal granuloma formation on unique myeloid DC-like cells. J Clin Invest 2007 Mar;117:605-15.
124. Kugathasan S, Saubermann L, Smith L, Kou D, Itoh J, Binion D, Levine A, Blumberg RS, Fiocchi C. Mucosal T-Cell immunoregulation varies in early and late inflammatory bowel disease. Gut December 2007;56:1696-1705.
125. Stern-Gnossar N, Nedvetski S, Markel G, Gazit R, Betser-Cohen G, Achdout H, Aker M, Blumberg RS, Davis DM, Appelmek B and Mandelboim O. Intercellular Transfer of CEA from Tumor Cells to NK Cells. J Immunol 2007;179:4424-4434.
126. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali K, Cross R, Sehy D, Blumberg RS and Vignali DAA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-569.
127. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Xavier RJ, Blumberg RS, Bhan AK, and Mizoguchi A. Contribution of goblet cell restoration by IL-22 to rapid attenuation of colitis. J Clin Invest 2007; In press.
128. Chen Z, Chen L, Qiao S-W, Nagaishi T, Blumberg RS. CEACAM1 inhibits proximal T cell receptor signaling by targeting ZAP-70. J Immunol 2007. Provisionally accepted.
129. Qiao S-W, Kobayashi K, Johansen F-E, Sollid LM, Andersen, JT, Milford E, Roopenian, DC, Lencer WI, Blumberg RS. Dependence of antibody-mediated presentation of antigen on FcRn. J Clin Invest 2007; Under revision.
130. Kaser A, Lee AH, Lefebvre C, Glickman J, Tilg H, Nieuwenhuis Edward ES, van der Velden AWM, Starnback MN, Higgins DE, Rioux JD, Glimcher, LH, Blumberg RS. Coordinate regulation of paneth cell function and intestinal inflammation by X box binding protein 1 as a risk factor for inflammatory bowel disease. Submitted.
50
Richard S. Blumberg, M.D.
Proceedings of Meetings:
1. Blumberg RS. Mucosal immunology in IBD: the role of epithelial cells. In: Tytgat GNJ, van Deventer SJH, Bartelsman JFWM, eds. Inflammatory Bowel Diseases. Lancaster: Kluwer, 1995:266-74.
2. Balk SP, Exley M, Blumberg RS. Antigen presentation by epithelial cells. In: Stallmach A, Zeitz M, Strober W, MacDonald TT, Lochs H, eds. Induction and modulation of gastrointestinal inflammation. Dordrecht: Kluwer Academic Publishers, 1999: 30-37.
3. Blumberg RS, Simister NE, Lencer W. Functional role of FcRn on intestinal epithelial cells. In: Stallmach A, Zeitz M, Strober W, MacDonald TT, Lochs H, eds. Induction and modulation of gastrointestinal inflammation. Dordrecht: Kluwer Academic Publishers, 1999: 38-49.
4. Blumberg RS. Role of epithelial cells in IBD. In: Emmrich J, ed. Inflammatory bowel diseases. Lancaster: Kluwer Academic Publishers, 1999:155-72.
5. Blumberg RS. Characterization of CD1d in mucosal immune function: an immuno-therapeutic target for inflammatory bowel disease. Keio J Med 2001;50:39-44.
6. Blumberg RS. The multiple roles of MHC class I-like molecules in mucosal immune function. Acta Odontologica Scandinavica 2001;59:139-44.
7. Bitonti A, Spiekermann G, Dumont J, Low S, Simister N, Peters R, Palombella V, Stattel J, Lencer W, Blumberg R. Transepithelial absorption of an erythropoietin-Fc fusion protein after delivery to the central airways. Resp Drug Delivery 2002;8:309-12.
8. Kaser A, Nieuwenhuis EES, Strober W, Fuss I, Colgan S, Blumberg RS. CD1d-restricted T cell pathways at the epithelial-lymphocyte-luminal interface. J Pediatr Gastroenterol Nutr 2004;l39:S719-22.
9. Kaser A, Nieuwenhuis EES, Corazza N, Iijima H, Yoshida M, Nagaishi T, Glickman J, Wirtz S, Galle S, Birkenbach M, Neurath M, Blumberg RS. The role of Epstein-Barr virus-induced gene 3 in driving Th2-associated intestinal inflammation. Dordrecht: Kluwer Academic Publishers, 2004:148-55.
10. Kaser A, Nieuwenhuis EES, Strober W, Mayer L, Fuss I, Colgan S, Blumberg RS. Natural killer T cells in mucosal homeostasis. New York: Annals New York Academy of Sciences, 2005:129;154-68.
11. Kaser A, Betz S, Brozovic S, Nagaishi T, Yoshida M, Corazza N, Colgan S, Young S, Exley M, Blumberg RS. Lipids and IBD: Microsomal triglyceride transfer protein – the new dimension? Dordrecht: Kluwer Academic Publishers, 2006: 36-45.
12. Nagaishi T, Pao L, Iijima H, Neel B, Blumberg RS. SHP-1-dependent, T cell inhibition by CEACAM1 isoforms expressing a long cytoplasmic tail domain in vivo. New York: Annals New York Academy of Sciences, 2006;1072:155-75.
51
Richard S. Blumberg, M.D.
13. Nieuwenhuis EES, Kaser A, Dougan S, Glickman J, Matsumoto T, Onderdonk A, Blumberg RS. CD1d: At the cusp of innate and adaptive Immunity in regulating Mucosal Inflammation. Dordrecht: Kluwer Academic Publishers, 2007:18-28.
14. Chen Z, Nagaishi T, Chen L, Iijima H, Nakajima A, Blumberg RS. CEACAM1 and the regulation of mucosal inflammation. Mucosal Immunology 2008; In press.
15. Mechanisms in the Gastrointestinal Tract: Assembling the Inflammatory Jig-Saw. 2008; In Press.
52
Richard S. Blumberg, M.D.
Reviews, Chapters and Editorials
1. Blumberg RS, Schooley RT. Lymphocyte markers and infectious diseases. Semin Hematol 1985;22:81-114.
2. Blumberg RS, Schooley RT. Epstein-Barr virus infection. The Immunocompromised Host 1985;2(4):1-12.
3. Schooley RT, Blumberg RS, Vogt M, Hartshorn KL, Hirsch MS. Perspectives for therapy of human immunodeficiency virus (HIV) infections. J Exp Pathol 1987;3:661-80.
4. Terhorst C, Alarcon B, Berkhout B, Blumberg R, Clevers H, Georgopoulous K, Hall C, Ley S, Versteegen J, Wileman T. Assembly of the T cell receptor/CD3 complex. In: Melchers F, ed. Progress in Immunology, Vol. VII. Berlin: Springer-Verlag, 1989:33-9.
5. Blumberg RS. Relapse of inflammatory bowel disease: a riddle wrapped inside a mystery within an enigma. Gastroenterology 1990;98:792-6.
6. Blumberg RS, Balk SP. Intraepithelial lymphocytes and their recognition of non-classical MHC molecules. Int Rev Immunol 1993;11:15-30.
7. Blumberg RS, Balk SP. Recognition of epithelial ligands by T-cells. Mucosal Immunology Update 1994;2:3-5.
8. Blumberg RS. Typhlitis. In: Taylor MB, Gollan JL, Peppercorn MA, Steer ML, Wolfe MM, eds. Gastrointestinal Emergencies. Baltimore: Williams and Wilkins, 1994:548-61.
9. Blumberg RS. An antigen shared by colon, eye, and joint and relevance for ulcerative colitis [editorial comment]. Inflammatory Bowel Disease 1995;1:88-9.
10. Blumberg RS, Gerdes D, Chott A, Porcelli SA, Balk SP. Structure and function of the CD1 family of MHC-like cell surface proteins. Immunol Review 1995;147:1-29.
11. Blumberg RS, Stenson W. Mucosal Immunity. In: Yamada T, Alpers DH, Owyang C, Powell D, Silverstein FE, eds. Textbook of Gastroenterology. Philadelphia: J.B. Lippincott, 1995:111-40.
12. Blumberg RS, Simister N, Christ AD, Israel EJ, Colgan SP, Balk SP. MHC-like molecules on mucosal epithelial cells. In: Kagnoff M, Kiyono H, eds. Essentials of Mucosal Immunology. San Diego: Academic Press, 1996:85-99.
13. Morales V, Snapper S, Blumberg RS. Probing gastrointestinal immune function: recent applications of transgenic and knockout technology. Current Opinion Gastroenterol 1996;12:755-83.
53
Richard S. Blumberg, M.D.
14. Blumberg RS, Colgan SP, Morales V, Polischuk J, Frantz M, Nusrat A, Balk SP. Nonclassical MHC class I molecules on human intestinal epithelial cells and their role in IEL function. In: Kaiserlian D, ed. Antigen Presentation by Intestinal Epithelial Cells. Austin: R.G. Landes Company, 1996:77-95.
15. Kim H, Balk SP, Blumberg RS. T cell selection and epithelial ligands in the gastrointestinal tract. In: Ernst P, Michetti P, Smith PD, eds. The immunobiology of Helicobacter pylori- from pathogenesis to prevention. New York: Lippincott-Raven, 1997:138-52.
16. Blumberg RS. The past as present. Gastroenterology 1997;112:1067.
17. Blumberg RS, Christ AD, Kim H, Balk SP. Role of intestinal cells as antigen presenting cells. Mucosal Immunol Update 1997;5:25-9.
18. Blumberg RS, Colgan SP, Balk SP. CD1d: Outside-in antigen presentation in intestinal epithelium? Clin Exp Immunol 1997;109:223-5.
19. Christ A, Blumberg RS. The intestinal epithelial cell: immunological aspects. Springer Semin Immunopathol 1997;18:449-61.
20. Blumberg RS. One size fits all: nonclassical MHC fulfill multiple roles in epithelial function. Am J Physiol 1998; 274 (Gastrointest. Liver Physiol): G227-G231
21. Blumberg RS. Food for thought. Gastroenterology 1998; 114:631.
22. Probert C, Blumberg RS. T cell receptor usage in intestine. Chemical Immunol 1998;71:27-39.
23. Kim HS, Blumberg RS. A nonclassical major histocompatibility complex molecule: CD1d expression by intestinal epithelial cells. In: Yoshikawa H, ed. Bioregulation and its dis-orders in the gastrointestinal tract. Tokyo: Blackwell Science Publishers,1998:291-301.
24. Blumberg RS, Mayer LM. Antigen presenting cells: epithelial cells. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, eds. Mucosal Immunology. San Diego: Academic Press, 1999:365-79.
25. Blumberg RS, Lencer WI, Zhu X, Kim H-S, Claypool S, Balk SP, Saubermann LJ, Colgan SP. Antigen presentation by intestinal epithelial cells. Immunol Lett 1999;69:7-11.
26. Blumberg RS. The leadership of innovation. Gastroenterology 1999;116:787.
27. Hershberg RM, Blumberg RS. What’s so (co)-stimulating about the intestinal epithelium? Gastroenterology 1999;117:726-36.
28. Blumberg RS. Mucosal immunity. In: Yamada T, Alpers DH, Laine L, Owyang C, Powel D, eds. Textbook of gastroenterology. Philadelphia: Lippincott Williams &
54
Richard S. Blumberg, M.D.
Wilkins, 1999, pp. 106-23.
29. Blumberg RS, Saubermann LJ, Strober W. Animal models of inflammatory bowel disease. Current Opin Immunol, 1999;11:648-56.
30. Blumberg RS. Characterization of CD1d in mucosal immune function: an immuno-therapeutic target for inflammatory bowel disease. Keio J Med 2000;49:177.
31. Blumberg RS. David and Goliath: Discovery in the industrial age of science. Gastroenterology 2000;119:5.
32. Pitman R, Blumberg R. First line of defense: The role of the intestinal epithelium as an active component of the mucosal immune system. J Gastroenterol 2000;35:805-14.
33. Blumberg RS, Strober WS. Inflammatory Bowel Disease. J Am Med Assoc 2001;285:643-7.
34. Wada K, Nakajima A, Blumberg RS. PPAR and inflammatory bowel disease: A new therapeutic target for ulcerative colitis and Crohn’s disease. Trends Mol Med 2001;7:329-31.
35. Saubermann LJ, Blumberg RS. Molecular immunology of mucosal T cells. In: Mahida Y, ed. Immunological aspects of gastroenterology. Dordrecht: Kluwer Academic Publishers. 2001, pp. 75-95.
36. Friedman S, Blumberg RS. Inflammatory Bowel Diseases. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of internal medicine. 15th Edition. Philadelphia: McGraw Hill. 2001, pp. 1679-92.
37. Watt SM, Teixeira AM, Blumberg RS, Kuroki M, Skubitz KM, Bates PA. The identifi-cation of critical adhesiotopes on the N-domain of human CEACAM1 required fore ho-mophilic interactions. Leukocyte Typing VII, 2001, pp. 663-6.
38. Matsuhashi N, Nakajima A, Wada K, Miki H, Saubermann L, Kubota N, Terauchi Y, Kadowaki T, Nagai R, Blumberg RS. Protective effects of PPAR in gastrointestinal mucosal injuries. Recent Res Devel Immunol 2002;4:227-233.
39. Blumberg RS, Strober WS. Inflammatory bowel disease. Annu Rev Immunol 2002;20:495-549.
40. Ryan M, Blumberg RS. Immunology of gastrointestinal malignancies. In Rustgi AK, Crawford J, eds. Gastrointestinal Cancers. Orlando: W.B. Saunders. 2003; 81-103.
41. Blumberg RS, Hershberg R. The bacterial, epithelial, lymphocyte interface. In: Targan S, Shannahan F, eds. Inflammatory Bowel Diseases: Bench to Bedside. Lancaster: Kluwer Academic Publishers. 2003; 121-46.
42. Blumberg RS, Stenson W. Mucosal immunity and inflammation. In: Yamada T, Alpers DH, Owyang C, Powell D, Silverstein E, eds. Textbook of Gastroenterology.
55
Richard S. Blumberg, M.D.
Philadelphia: J.B. Lippincott, 2003; 117-50.
43. Blumberg RS. Regulation of mucosal lymphocytes by CEACAM1. Mucosal Immunology Update. 2003;11:3-4.
44. Mestecky J, Blumberg RS, Kiyono H, McGhee JR. The mucosal immune system. In: Paul WE, ed. Fundamental Immunology. Fifth Edition. Philadelphia: Lippincott-Raven Publishers. 2003; 965-1020.
45. Barrett T, Snapper S, Blumberg RS. T lymphocyte trafficking. In: Sartor RB, Sandborn WJ, eds. Kirshner’s Inflammatory Bowel Diseases. Philadelphia: W. B. Saunders Com-pany. 2004;80-9.
46. Kaser A, Blumberg RS. The other way round: Colitis regulates regulatory T cells. Gastroenterology 2004;126:1903-6.
47. Friedman S, Blumberg RS. Infermedad inflamatoria intestinal. In: Méndez-Sánchez N, Uribe M, eds. Conceptos Actuales en Gastroenterolgia. First Edition. Mexico City: McGraw-Hill Interamericana. 2004, Chapter 56.
48. Friedman S, Blumberg RS. Inflammatory Bowel Diseases. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of Internal Medicine. 16th Edition. Philadelphia: McGraw Hill. 2005:1776-89.
49. Blumberg RS, Lencer WI. Antibodies in the breakdown lane. Nat Biotechnol 2005;10:1232-4.
50. Nieuwenhuis EES, Blumberg RS. Epithelial Cells. Neurath MF, Blumberg RS, eds. The role of the epithelial barrier in inflammatory bowel disease. Adv Exp Med Biol 2006; 579:108-16.
51. Johansen FE, Yen EH, Dickinson B, Yoshida M, Claypool S, Blumberg RS and Lencer WI. Biology of Gut Immunoglobulins. In: Johnson, ed. Textbook of Gastrointestinal Physiology. 2006;43:1067-90.
52. Owen GS, Blumberg RS. Carcinoembryonic cell adhesion molecule 1 in immune regulation. Nat Rev Immunol 2006;6:433-46.
53. Blumberg RS. Presentation of the Julius M. Friedenwald medal to Norton J. Green-berger, M.D. Gastroenterology 2006;130:2210-4.
54. Yoshida M, Masuda A, Kuo T, Koyayashi K, Claypool S, Takagawa T, Kutsumi H, Azuma T, Lencer W, and Blumberg RS. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springers Sem Immunopath 2006; 28:397-403.
55. Probert CSJ, Vaubermann LJ, Balk S, Blumberg RS. Repertoire of alpha beta T cell receptor in the intestine. Immunol Rev 2007;215:215-25.
56
Richard S. Blumberg, M.D.
56. Qiao SW, Lencer WI., Blumberg RS. How the controller is controlled – neonatal Fc receptor expression and immunoglobulin G homeostasis. Immunology 2006;120:145-7
57. Dougan S, Kaser A, Blumberg RS. CD1 expression on antigen presenting cells. Current Topics Micro Immunol 2007;314:113-41.
58. van Dieren JM, van der Woude CJ, Kuipers EJ, Escher JC, Samson JN, Blumberg RS, Nieuwenhuis EES. The role of CD1d restricted NKT cells in the intestine. Inflammatory Bowel Dis Sep 2007; 13(9):1146-52.
59. Sartor RB, Blumberg RS, Braun J, Elson CO, Mayer LF. CCFA microbial-host interactions workshop: highlights and key observations. Inflamm Bowel Dis 2007 May;13:600-19.
60. Zeissig S, Kaser A, Dougan S, Nieuwenhuis EES and Blumberg RS. Role of NKT cells in Intestinal Immunity. Am J Physiol Gastrointest Liver Physiol 2007 August 23 [Epub ahead of print]
61. Blumberg RS and MacDonald TT. Mucosal Immunology: A frontier no longer. Mucosal Immunology, 2008; In press.
57
Richard S. Blumberg, M.D.
Books, Monographs, and Text Books:
Neurath MF, Blumberg RS, editors. Immune mechanisms in inflammatory bowel disease. Advances in Experimental Medicine and Biology, (Volume 579) Georgetown, Texas: Landes Biosciences; 2006
58
Richard S. Blumberg, M.D.
Clinical Communications:
1. Blumberg R, Kelsey P, Perrone T, Laquaglia M, Ferruci A. Cryptosporidiosis and cytomegalovirus associated acalculous gangrenous cholecystitis. Am J Med 1984; 76:1118-23.
2. Gendleman D, Blumberg R, Sadun A. Ocular loa loa. Ophthalmology 1984;91:300.
3. Case Records of the Massachusetts General Hospital [Case 15-1984]. N Engl J Med 1984;310:972-81.
4. Case Records of the Massachusetts General Hospital [Case 48-1984]. N Engl J Med 1984;311:1425-32.
5. Blumberg RS, Chopra S, Ibrahim R, Crawford J, Farraye FA, Zeldis JB, Berman M. Hepatocellular carcinoma in idiopathic hemochromatosis following reversal of cirrhosis. Gastroenterology 1988;95:1399-1402.
6. Blumberg RS, Compton CC. Case Records of the Massachusetts General Hospital [Case 33-1993]. N Engl J Med 1993;329:561-8.
7. Blumberg RS. “Golden Age” of immunology illuminates inflammatory bowel disease. Gastroenterology Observer 2000;19:4-5.
59
Richard S. Blumberg, M.D.
Educational Materials:
1. Blumberg RS. Gastrointestinal manifestations of AIDS. 1989. Syllabus for Comprehensive Review of Gastroenterology, Harvard Medical School (updated annually 1989-1998).
2. Blumberg RS. Hepatic manifestations of AIDS. Syllabus for Comprehensive Review of Gastroenterology, Harvard Medical School, 1999 (updated annually, 1999-2002).
3. Blumberg RS. How IBD evolves – new insights. Syllabus for Comprehensive Review of Gastroenterology, Harvard Medical School, 2003 (updated annually, 2003-).
60
Richard S. Blumberg, M.D.
Nonprint Materials
GenBank SubmissionAccession: U21960Definition: Mus musculus calcium modulating cyclophilin ligand (CAML) gene, complete
cdsAuthors: Kim HS, Morales VM, Dass C, Encinas J, Teitell M, Blumberg RSUsers: Complementary DNA of mouse CAML; utility to lymphocyte signal transduction
field.
GenBank submissionAccession: AF078112Definition: Mus musculus calcium signal-modulating ligand (CAMLg) gene, promoter region
and partial cds; and unknown genesAuthors: Morales VM, Snapper SB, Blumberg Users: Genomic DNA of mouse CAML; utility to lymphocyte signal transduction field.
61
Richard S. Blumberg, M.D.
Patents:
Blumberg RS, Simister NE, Lencer WIReceptor Specific Transepithelial Transport of Therapeutics U.S. Patent Number: 6,030,613.Date of Patent: February 29, 2000.
Blumberg RS, Simister NE, Lencer WIReceptor Specific Transepithelial Transport of Immunogens U.S. Patent Number: 6,086,875Date of Patent: July 11, 2000
Blumberg RS, Simister NE, Lencer WIReceptor Specific Transepithelial Transport of Therapeutics U.S. Patent Number: 6,485,726.Date of Patent: November 26, 2002
Blumberg RST Cell Inhibitory Receptor Compositions and Uses Thereof European Patent Number: GE19A33/P-EP/WODate of Patent: July 11, 2003U.S. Patent Number: 6,852,320.Date of Patent: February 28, 2005
Blumberg RS, Lencer WI, Simister NE, Bitonti ACentral Airway Administration for Systemic Delivery of TherapeuticsU.S. Publication Number: 2004/0063912 A1.Date of Publication: April 1, 2004
Blumberg RS, Bhan AK, Utku NTherapeutic Anti-BGP (CD66a) Antibodies and Uses ThereofProvisional European Patent Application No. EP02 020 334.5
Strober W, Fuss IJ, Heller F, Blumberg RSMethods of Treating and Preventing Colitis Involving IL-13 and NK-T Cells.International Application NO. PCT/US02/18790
Blumberg RSAnti-Inflammation Provided by Inhibition of Microsomal Triglyceride Transfer ProteinProvisional U.S. Patent Application No. 60/457,048
Serhan C, Blumberg RS.Use of Resolvins to Treat Gastrointestinal DiseasesProvisional U.S. Patent Application
Utku N, Blumberg RSUse of Agents derived from CEACAM1 for the treatment of inflammatory diseases
62
Richard S. Blumberg, M.D.
Provisional U.S. and European Patent Application
Blumberg RS, Kaser A, Rioux J, Glimcher LPolymorphisms in the Human XBP-1 Gene are associated with Inflammatory Bowel DiseaseXBPI patentProvisional U.S. and European Patent ApplicationU.S. Provisional Patent Application Number: 60/846, 950 (HUI-060-1)
Blumberg, RSIdentification of compounds that bind biliary glycoprotein and affect cytotoxic T lymphocyte activityDate of Patent: November 7, 2006U.S. Patent Number: 7,132, 255 B2
63
Richard S. Blumberg, M.D.
Abstracts:
1. Christ AD, Saubermann LUJ, Rousson V, Blumberg RS, Fried M. Oligoclonality of gastric T lymphocytes as defined by objective measure of T cell receptor-beta chain CDR3 size. Gastroenterology 2001;120:A322.
2. Dickinson BL, Claypool SM, Blumberg RS, Lencer WI. Functional interaction of calmodulin with the Fc--receptor FcRn. Gastroenterology 2001;120:A699.
3. Kim H, Han S, Balk S, Blumberg R. CD1d mediates protective immune response in Listeria infection. Gastroenterology 2002;122:A273.
4. Zhu, X, Peng J, Dickinson B, Chen D, Iijima H, Lencer WI, Blumberg RS. Calnexin facilitates the assembly of the neonatal Fc receptor for IgG with [beta]2-microglobulin in the endoplasmic reticulum. FASEB J 2003; C107.
5. Wirtz SJ, Becker C, Nieuwenhuis EES, Birkenbach M, Blumberg RS, Neurath MF. in Vivo and in Vitro analysis of the functional role of Epstein-Barr virus-induced gene 3 (EBI3) for regulation of Th2 mediated immune responses. Gastroenterology 2003:124:P143.
6. Shirane K, Hokama A, Mizoguchi Ehida M, Snapper SB, Terhorst C, Blumberg RS, Mizoguchi A. Cross-linking of immunological synapse on CD4+ T cells by an epithelial lectin contributes to the exacerbation of colitis. Gastroenterology 2004:126;A154.
7. Dickinson BL, Blumberg RS, Lencer WI. FcRn-mediated transcytosis of IgG across mucosal barriers is regulated by calmodulin. Gastroenterology 2004;126:S1027 (Poster of Distinction).
8. Shimomura Y, de John UP, Rietdijk ST, Mizoguchi E, Sugimoto K, Yoshida M, Blumberg RS, Terhorst C, Bhan AK, Mizoguchi A. Exogenous IL-2 is required to elucidate the regulatory effect of CD4+CD25+ T cells on the development of colitis. Gastroenterology 2004;126:T1065.
9. Kastunori S, Hokama A, Shimomura Y, Ogawa A, Yoshida M, Snapper SB, Terhorst C, Blumberg RS, Mizoguchi A. Intestinal inflammatory conditions confer a reactivity of CD4+ T cells to galectin-4, a pathogenic mediator for the exacerbation of colitis. Gastroenterology 2005;128:385.
10. Yoshida M, Kuo TT, Kaser A, Nagaishi T, Claypool SM, Mizoguchi E, Mizoguchi A, Wakatsuki Y, Roopenian DC, Lencer WI, Blumberg RS. Neonatal Fc receptor transports IgG into luminal secretions for delivery of bacterial antigens to mucosal dendritic cells. Gastroenterology 2005;128:686.
11. Nagaishi T, Iijima H, Pao L, Chen D, Glickman J, Nakajima A, Neel BG, Blumberg RS. T cell inhibition by CEACAM1 isoforms expressing a long cytoplasmic domain. Gastroenterology 2005;128:S-1399.
64
Richard S. Blumberg, M.D.
12. Sugimoto K, Ogaswa A, Mizoguchi E, Nagaishi T, Blumberg RS, Mizoguchi A. Bhan AK. Immature myeloid dendritic cells induce intestinal granulomas under Th1 environment conditions. Gastroenterology 2005;128:W1451.
13. Wirtz SJ, Birkenbach MP, Galle PR, Blumberg RS, Neurath MF. A key pathogenic role of IL-27/wsx0-1 signaling in experimental septic peritonitis. Gastroenterology 128:461.
14. Ogawa A, Rietkijik ST, de Jong YP, Blumberg RS, Cox T, Mizoguchi A. TCR????fĀ IELs contribute to elicit the regulatory activity to Treg cells through IL-2 dependent pathway. Gastroenterology 2005;128:S1401.
15. Egawa S, Iijima H, Shinzaki S, Ishii S, Irie T, Nishida T, Yasumaru M, Kanto T, Tsuijii M, Hayashi N, Kawano S, Utku N, Blumberg RS, Tsuji S. Contribution of CEACAM1, a candidate therapeutic target for inflammatory bowel disease, is involved in the induction of T cell immune tolerance. Gastroenterology 2005;128:S1388.
65